# EDGAR Filing Document

**Accession Number:** 0001167379
**File Stem:** 0001167379-26-000013
**Filing Date:** 2026-2
**Character Count:** 183772
**Document Hash:** 73bcd6ed11b1679a73cbb325c89089ac
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001167379-26-000013.hdr.sgml**: 20260224

**ACCESSION NUMBER**: 0001167379-26-000013

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 6

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260224

**DATE AS OF CHANGE**: 20260224

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALCON INC
- **CENTRAL INDEX KEY:** 0001167379
- **STANDARD INDUSTRIAL CLASSIFICATION:** OPHTHALMIC GOODS [3851]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 980205094
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-31269
- **FILM NUMBER:** 26672271

**BUSINESS ADDRESS:**
- **STREET 1:** 6201 SOUTH FREEWAY
- **CITY:** FORT WORTH
- **STATE:** TX
- **ZIP:** 76134
- **BUSINESS PHONE:** 817 293 0450

**MAIL ADDRESS:**
- **STREET 1:** CHEMIN DE BLANDONNET 8
- **STREET 2:** 1214 VERNIER
- **CITY:** GENEVA
- **STATE:** V8
- **ZIP:** 0000

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

_________________

**FORM 6-K** 

_________________

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE**

**SECURITIES EXCHANGE ACT OF 1934**

**February 24, 2026**

**Commission File Number: 001-31269** 

_________________

**ALCON INC.** 

(Registrant Name)

**Rue Louis-d'Affry 6** <br>**1701 Fribourg, Switzerland** 

(Address of principal executive office)

_________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ &nbsp;&nbsp;&nbsp;&nbsp;Form 40-F ☐

------

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 99.1 | <u>[Press release issued by Alcon Inc. dated February 24, 2026](q42025pressrelease.htm)</u> |
| 99.2 | <u>[Alcon Inc. Interim Financial Report](q42025interimfinancialrepo.htm)</u> |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | **ALCON INC.** | **ALCON INC.** |
| Date: | February 24, 2026 | By: | /s/ David J. Endicott |
|  |  | Name: David J. Endicott | Name: David J. Endicott |
|  |  | Title: Authorized Representative | Title: Authorized Representative |
| Date: | February 24, 2026 | By: | /s/ Timothy C. Stonesifer |
|  |  | Name: Timothy C. Stonesifer | Name: Timothy C. Stonesifer |
|  |  | Title: Authorized Representative | Title: Authorized Representative |

---

## Exhibit 99.1

![pressreleaseheader.jpg](pressreleaseheader.jpg)

**Alcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate Sales**

**• Fourth-quarter 2025 sales of $2.7 billion, up 9% on a reported basis, or up 7% constant currency**<sup>1</sup> **(cc), versus fourth-quarter 2024**

**• Fourth-quarter 2025 diluted EPS of $0.44; core diluted EPS**<sup>2</sup> **of $0.78** 

**• Generated $2.3 billion of cash from operations and $1.7 billion of<br>free cash flow**<sup>3</sup> **in full-year 2025**

**• Returned $848 million to shareholders through share repurchases and dividends** 

**Ad Hoc Announcement Pursuant to Art. 53 LR** 

**Geneva, February 24, 2026 -** Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2025. For the fourth quarter of 2025, sales were $2.7 billion, up 9% on a reported basis and up 7% on a constant currency basis<sup>1</sup>, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.44 and core diluted earnings per share<sup>2</sup> of $0.78 in the fourth quarter of 2025.

"2025 was a pivotal and productive year for Alcon. Despite softer markets, we successfully launched a wave of innovative new products that fueled sales acceleration as the year progressed," said David J. Endicott, Alcon's Chief Executive Officer. "As we look to 2026, we're encouraged by the momentum we're carrying into the year and confident in our ability to continue to deliver sustainable growth and long-term value. Our outlook reflects a balanced view of market conditions combined with the progress made with new product launches, giving us a strong foundation as we move forward."

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** |
| **Fourth-quarter and full-year 2025 key figures**<br> | **2025** | **2024** | **2025** | **2024** |
| Net sales ($ millions) | 2702 | 2477 | 10319 | 9836 |
| Operating margin (%) | 11.6% | 15.9% | 13.2% | 14.4% |
| Diluted earnings per share ($) | 0.44 | 0.57 | 1.98 | 2.05 |
| **Core results (non-IFRS measure)**<sup>2</sup> |  |  |  |  |
| Core operating margin (%) | 19.0% | 20.1% | 19.8% | 20.6% |
| Core diluted earnings per share ($) | 0.78 | 0.72 | 3.07 | 3.05 |
| **Cash flows ($ millions)** |  |  |  |  |
| Net cash flows from operating activities |  |  | 2271 | 2077 |
| Free cash flow (non-IFRS measure)<sup>3</sup> |  |  | 1733 | 1604 |

---

1. Constant currency (cc) is a non-IFRS measure. An explanation of non-IFRS measures can be found in the 'Non-IFRS measures as defined by the Company' section.

2. Core results, such as core gross margin, core operating income, core operating margin and core diluted EPS, are non-IFRS measures. An explanation of non-IFRS measures can be found in the 'Non-IFRS measures as defined by the Company' section.

3. Free cash flow is a non-IFRS measure. An explanation of non-IFRS measures can be found in the 'Non-IFRS measures as defined by the Company' section.

------

**Fourth-quarter and full-year 2025 results**

Reported net sales for the fourth quarter of 2025 were $2.7 billion, up 9% versus the fourth quarter of 2024. Excluding favorable currency impacts of 2%, sales were up 7% on a constant currency basis. Reported net sales for the full-year 2025 were $10.3 billion, up 5% compared to full-year 2024. Excluding favorable currency impacts of 1%, sales were up 4% on a constant currency basis.

The following table highlights net sales by segment for the fourth quarter and full-year of 2025:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Change %** | **Twelve months ended December 31** | **Twelve months ended December 31** | **Change %** |
|<br>($ millions unless indicated otherwise) | **2025** | **2024** | $**cc**<sup>1</sup><br>**(non-IFRS measure)** | **2025** | **2024** | $**cc**<sup>1</sup><br>**(non-IFRS measure)** |
| **Surgical** |  |  |  |  |  |  |
| Implantables | 474 | 456 | 2 | 1782 | 1775 |  |
| Consumables | 794 | 738 | 5 | 3028 | 2861 | 5 |
| Equipment/other | 277 | 229 | 18 | 941 | 886 | 6 |
| **Total Surgical** | **1545** | **1423** | **6** | **5751** | **5522** | **4** |
| **Vision Care** |  |  |  |  |  |  |
| Contact lenses | 683 | 638 | 4 | 2770 | 2609 | 5 |
| Ocular health | 474 | 416 | 12 | 1798 | 1705 | 6 |
| **Total Vision Care** | **1157** | **1054** | **7** | **4568** | **4314** | **5** |
| **Net sales** | **2702** | **2477** | **7** | **10319** | **9836** | **4** |

---

**Net sales by segment**

Fourth quarter

**Surgical**

Surgical net sales, which include implantables, consumables and equipment/other, were $1.5 billion, an increase of 9% on a reported basis and 6% on a constant currency basis versus the fourth quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Implantables net sales were $474 million, an increase of 4%. Excluding favorable currency impacts of 2%, Implantables net sales increased 2% constant currency. This growth reflects strong performance by *PanOptix* Pro in the US, partially offset by continued competitive pressures, particularly in international markets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consumables net sales were $794 million, an increase of 8%. Excluding favorable currency impacts of 3%, Consumables net sales increased 5% constant currency. Growth was driven by cataract and vitreoretinal procedural growth, as well as price increases.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Equipment/other net sales were $277 million, an increase of 21%. Excluding favorable currency impacts of 3%, Equipment/other net sales increased 18%. This growth was led by recent equipment launches, including the *Unity* platform.

------

**Vision Care**

Vision Care net sales, which include contact lenses and ocular health, were $1.2 billion, an increase of 10% on a reported basis and 7% on a constant currency basis versus the fourth quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Contact lenses net sales were $683 million, an increase of 7%. Excluding favorable currency impacts of 3%, Contact lenses net sales increased 4% constant currency. This growth was led by price increases and product innovation, partially offset by declines in legacy products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Ocular health net sales were $474 million, an increase of 14%. Excluding favorable currency impacts of 2%, Ocular health net sales increased 12% constant currency. Growth was led by our portfolio of dry eye products, including *Tryptyr* and *Systane*.

Full year

**Surgical**

Surgical net sales were $5.8 billion, an increase of 4% on a reported and constant currency basis versus the full-year 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Implantables net sales were $1.8 billion, in line with the prior year period on a reported and constant currency basis. These results reflect the launch of *PanOptix* Pro in the US, as well as soft market conditions and competitive pressures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consumables net sales were $3.0 billion, an increase of 6%. Excluding favorable currency impacts of 1%, Consumables net sales increased 5% constant currency. Growth was driven by vitreoretinal procedural growth and price increases, partially offset by soft cataract market conditions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Equipment/other net sales were $941 million, an increase of 6% on a reported and constant currency basis, as sales of recently launched equipment, including *Unity* VCS, were partially offset by declines in legacy equipment.

**Vision Care**

Vision Care net sales were $4.6 billion, an increase of 6% on a reported basis and 5% on a constant currency basis versus the full-year 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Contact lenses net sales were $2.8 billion, an increase of 6%. Excluding favorable currency impacts of 1%, Contact lenses net sales increased 5% constant currency, primarily driven by price increases and product innovation, partially offset by declines in legacy products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Ocular health net sales were $1.8 billion, an increase of 5%. Excluding unfavorable currency impacts of 1%, Ocular health net sales increased 6% constant currency. Growth was led by our portfolio of dry eye products, including *Tryptyr* and *Systane*. The prior year period included sales of certain eye drops in China which were divested and out-licensed in late 2024.

------

**Operating income**

Fourth quarter

Operating income was $313 million (-21%, -27% cc), compared to $395 million in the prior year period. Operating margin decreased 4.3 percentage points. The current year period included sales and marketing investments behind new product launches, increased investment in research and development ("R&D"), including from recent acquisitions, incremental tariffs and acquisition and integration related items, partially offset by favorability from annual incentive compensation and price increases. The prior year period included a net gain related to the divestment of certain product rights in China. Excluding a positive 0.8 percentage point impact from currency, operating margin decreased 5.1 percentage points on a constant currency basis.

Adjustments to arrive at core operating income in the current year period were $201 million, mainly due to $175 million of amortization and $22 million of acquisition and integration related items. Adjustments to arrive at core operating income in the prior year period were $103 million, mainly due to $169 million of amortization, partially offset by a $57 million net gain related to the divestment of certain product rights in China.

Core operating income was $514 million (+3%, -2% cc), compared to $498 million in the prior year period. Core operating margin decreased 1.1 percentage points as the current year period included sales and marketing investments behind new product launches, increased investment in R&D, including from recent acquisitions and incremental tariffs, partially offset by favorability from annual incentive compensation and price increases. Excluding a positive 0.5 percentage point impact from currency, core operating margin decreased 1.6 percentage points on a constant currency basis.

Full year

Operating income was $1.4 billion (-4%, -5% cc), down slightly from the prior year period. Operating margin decreased 1.2 percentage points. The current year period included sales and marketing investments behind new product launches, increased investment in R&D, including from recent acquisitions, incremental tariffs, acquisition and integration related items and product discontinuation charges in Vision Care. The decline in operating margin was partially offset by price increases, fair value remeasurements of investments in associated companies and favorability from annual incentive compensation. The prior year period included a net gain related to the divestment of certain product rights in China. Excluding a positive 0.1 percentage point impact from currency, operating margin decreased 1.3 percentage points on a constant currency basis.

Adjustments to arrive at core operating income in the current year period were $679 million, mainly due to $696 million of amortization, $58 million of acquisition and integration related items and $44 million of product discontinuation charges, partially offset by $142 million on fair value remeasurements of investments in associated companies. Adjustments to arrive at core operating income in the prior year period were $614 million, mainly due to $667 million of amortization, partially offset by a $57 million net gain related to the divestment of certain product rights in China.

Core operating income was $2.0 billion (+1%, 0% cc) in both the current and prior year periods. Core operating margin decreased 0.8 percentage points. The current year period included sales and marketing investments behind new product launches, increased investment in R&D, including from recent acquisitions and incremental tariffs, partially offset by price increases and favorability from annual incentive compensation. Excluding a positive 0.1 percentage point impact from currency, core operating margin decreased 0.9 percentage points on a constant currency basis.

------

**Taxes**

Fourth quarter

Reported tax expense was $47 million, compared to $65 million in the prior year period, and the average reported tax rate was 17.8%, compared to 18.6% in the prior year period. Core tax expense was $83 million, compared to $93 million in the prior year period, and the average core tax rate was 17.8%, compared to 20.6% in the prior year period. Both the average reported and core tax rates were lower in the current year period due to a more favorable mix of pre-tax income/(loss) across geographical tax jurisdictions and higher discrete tax benefits in the current year period.

Full year

Reported tax expense was $180 million, compared to $238 million in the prior year period, and the average reported tax rate was 15.5%, compared to 18.9% in the prior year period. Core tax expense was $323 million, compared to $355 million in the prior year period, and the average core tax rate was 17.5%, compared to 19.0% in the prior year period. The average reported tax rate was lower in the current year period due to a non-taxable gain. In addition, both the average reported and core tax rates benefited from higher discrete tax benefits in the current year period.

**Diluted earnings per share**

Fourth quarter

Diluted earnings per share of $0.44 decreased 23%, or 30% on a constant currency basis, versus the prior year period, primarily due to lower operating income. Core diluted earnings per share of $0.78 increased 8%, or 2% on a constant currency basis, versus the prior year period.

Full year

Diluted earnings per share of $1.98 decreased 3%, or 5% on a constant currency basis, primarily due to lower operating income and higher non-operating income & expense<sup>4</sup>, partially offset by lower tax expense. Core diluted earnings per share of $3.07 increased 1%, or 0% on a constant currency basis, versus the prior year period.

**Cash flow highlights**

Net cash flows from operating activities amounted to $2.3 billion for the full-year 2025, compared to $2.1 billion in the prior year period. Free cash flow was $1.7 billion for the full-year 2025, compared to $1.6 billion in the prior year period, primarily due to increased cash flows from operating activities.

**Capital allocation**

For the full-year 2025, the company returned $848 million to shareholders. Capital returns include the repurchase of approximately 8.4 million shares<sup>5</sup> for $682 million and dividend payments of $166 million. Additionally, as of January 20, 2026, the Company completed its $750 million share repurchase program.

Proposed dividend

The Company's Board of Directors proposed a dividend of CHF 0.28 per share, based on 2025 financial results. The Company's shareholders will vote on this proposal at the 2026 Annual General Meeting ("AGM") on April 30, 2026.

4. Non-operating income & expense includes interest expense, other financial income & expense and share of loss from associated companies.

5. On February 25, 2025, the Board authorized the repurchase of up to $750 million of the Company's common shares. Refer to Note 5 of the Condensed Consolidated Interim Financial Statements for details regarding the share repurchase program.

------

**Efficiency measures**

The Company has undertaken a series of operational improvements and infrastructure investments to drive efficiencies across the organization. These initiatives have enabled the Company to identify approximately $100 million of run-rate savings, of which approximately $50 million is expected to benefit 2026. The total program cost is estimated at $150 million, with implementation expected to be completed in 2026.

**2026 outlook**

Beginning with its 2026 outlook, the Company is updating the way it presents guidance to align with the framework and priorities outlined at its 2025 Capital Markets Day. The Company's 2026 outlook is provided in the table below.

---

| | |
|:---|:---|
| **2026 outlook**<sup>6</sup> | **as of February** |
| Net sales growth vs. prior year (cc)<sup>1</sup><br><sup>(non-IFRS measure)</sup> | +5% to +7% |
| Core operating margin<sup>2</sup> change vs. prior year (cc)<sup>1</sup><br><sup>(non-IFRS measure)</sup> | +70 to +170 bps |
| Core diluted EPS<sup>2</sup> growth vs. prior year (cc)<sup>1</sup><br><sup>(non-IFRS measure)</sup> | +9% to +12% |

---

This outlook assumes the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Aggregated markets grow approximately 3% to 4%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Company expects a full-year tariff impact, net of mitigating actions, of approximately $125 to $175 million, which is expected to pressure cost of net sales.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Exchange rates as of the end of January 2026 prevail through year-end. As of the end of January, the expected currency impact to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Net sales growth is +120 basis points,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Core operating margin change is +15 basis points, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Core diluted EPS growth is +230 basis points.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-operating expense<sup>4</sup> for FY 2026 is expected to be between $200 and $220 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The core effective tax rate<sup>7</sup> for FY 2026 is expected to be approximately 20%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Capital expenditures are expected to be mid-single digits as a percentage of sales.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Approximately 498 million weighted-averaged diluted shares.

6. The forward-looking guidance included in this press release cannot be reconciled to the comparable IFRS measures without unreasonable effort, because we are not able to predict with reasonable certainty the ultimate amount or nature of exceptional items in the fiscal year. Refer to the section 'Non-IFRS measures as defined by the Company' for more information.

7. Core effective tax rate, a non-IFRS measure, is the applicable annual tax rate on core taxable income. For additional information, see the explanation regarding reconciliation of forward-looking guidance in the 'Non-IFRS measures as defined by the Company' section.

------

**Board Elections at Alcon's 2026 AGM**

Mr. Scott Maw will not stand for re-election to the Board of Directors at Alcon's 2026 AGM on April 30, 2026. "Our Board and leadership team are deeply grateful for Scott's dedication, judgment and commitment to Alcon as one of our founding board members and the Chair of our Audit and Risk Committee," said F. Michael Ball, Alcon's Chair of the Board.

The Board of Directors proposes the election of R. Scott Herren, an accomplished financial executive and public company board member who most recently served as Chief Financial Officer for Cisco Systems, Inc. If elected, Mr. Herren is expected to be appointed Chair of the Audit and Risk Committee.

The Board of Directors also proposes the re-election of all other current members of the Board, including the Chair of the Board.

**Webcast and Conference Call Instructions**

The Company will host a conference call on February 25, 2026 at 8:00 a.m. Eastern Time / 2:00 p.m. Central European Time to discuss its fourth-quarter 2025 earnings results. The webcast can be accessed online through Alcon's Investor Relations website, i.e. investor.alcon.com. Listeners should log on approximately 10 minutes in advance. A replay will be available online within 24 hours after the event. To listen the Company's conference call, click on the link:

https://investor.alcon.com/news-and-events/events-and-presentations/event-details/2026/Alcons-Full-Year-2025-Earnings-Call-2026-WO8uNd9SMd/default.aspx

The Company's fourth-quarter 2025 press release, interim financial report and supplemental presentation materials, as well as its 2025 Annual Report, can be found online through Alcon's Investor Relations website, or by clicking on the link:

https://investor.alcon.com/news-and-events/events-and-presentations/event-details/2026/Alcons-Full-Year-2025-Earnings-Call-2026-WO8uNd9SMd/default.aspx

Additionally, Alcon's 2025 Annual Report is available at https://investor.alcon.com/financials/annual-reports/default.aspx and its 2025 Annual Report on Form 20-F filed today with the US Securities and Exchange Commission on https://investor.alcon.com/financials/sec-filings/default.aspx. Alcon shareholders may receive a hard copy of either of these documents, each of which contains our complete audited financial statements, free of charge, upon request.

**Cautionary Note Regarding Forward-Looking Statements** 

This press release contains, and our officers and representatives may from time to time make, certain "forward-looking statements" within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "intend," "commitment," "look forward," "maintain," "plan," "goal," "seek," "target," "assume," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our 2026 outlook, liquidity, revenue, revenue growth, gross margin, operating margin, core operating margin, core operating margin growth, effective tax rate, foreign currency exchange movements, tariff impact, nonoperating expenses, earnings per share, earnings per share growth, operating cash flow, free cash flow, our plans and decisions relating to various capital expenditures, capital allocation priorities and other discretionary items such as our market growth assumptions, our social impact and sustainability plans, targets, goals and expectations, and generally, our expectations concerning our future performance.

------

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict such as: cybersecurity breaches and technology failures that could disrupt operations; our ability to effectively manage the risks associated with transformational information technology changes such as the ethical use of artificial intelligence and disruptive technologies and the migration to cloud-based platforms; compliance with data privacy, identity protection and information security laws, particularly with the increased use of artificial intelligence; the impact of a disruption in our global supply chain, including the effect of tariffs, or important facilities, particularly when we single-source or rely on limited sources of supply; our reliance on outsourcing key business functions; the increasingly challenging economic, political and legal environment in China; global and regional economic, financial, monetary, legal, tax, political and social change; our ability to comply with anti-corruption, anti-bribery, export control, trade sanction, or similar laws; our ability to attract and retain qualified personnel; our ability to manage the risks associated with operating as a third party contract manufacturer; our success in completing strategic acquisitions, including equity investments in early-stage companies, on favorable terms or at all, and in integrating acquired businesses; the success of our research and development efforts, including our ability to innovate to compete effectively; our ability to manage the rapid evolution and adoption of artificial intelligence; terrorism, war and similar events; our ability to forecast sales demand and manage our inventory levels and the changing buying patterns of our customers; pricing pressure from changes in third party payor coverage and reimbursement methodologies; our ability to comply with all laws to which we may be subject; the ability to obtain regulatory clearance and approval of our products as well as compliance with any post-approval obligations, including quality control of our manufacturing; the effect of product recalls or voluntary market withdrawals; our ability to manage social impact and sustainability matters; our ability to properly educate and train healthcare providers on our products; our ability to protect our intellectual property; the accuracy of our accounting estimates and assumptions, including pension and other post-employment benefit plan obligations and the carrying value of intangible assets, and the adequacy of our financial reporting, accounting practices and internal controls; our ability to service our debt obligations; the need for additional financing through the issuance of debt or equity; the effects of litigation, including product liability lawsuits and governmental investigations; legislative, tax and regulatory reform; the impact of being listed on two stock exchanges; the ability to declare and pay dividends; the different rights afforded to our shareholders as a Swiss corporation compared to a US corporation; the effect of maintaining or losing our foreign private issuer status under US securities laws; and the ability to enforce US judgments against Swiss corporations.

Additional factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this press release speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise. We also undertake no obligation to update the 2026 outlook as circumstances evolve.

**Intellectual Property**

This report may contain references to our proprietary intellectual property. All product names appearing in *italics* or ALL CAPS are trademarks owned by or licensed to Alcon Inc. Product names identified by a "®" or a "™" are trademarks that are not owned by or licensed to Alcon or its subsidiaries and are the property of their respective owners.

------

**Non-IFRS measures as defined by the Company**

Alcon uses certain non-IFRS metrics when measuring performance, including when measuring current period results against prior periods, including core results, percentage changes measured in constant currency, EBITDA, free cash flow and net (debt)/liquidity.

Because of their non-standardized definitions, the non-IFRS measures (unlike IFRS measures) may not be comparable to the calculation of similar measures of other companies. These supplemental non-IFRS measures are presented solely to permit investors to more fully understand how Alcon management assesses underlying performance. These supplemental non-IFRS measures are not, and should not be viewed as, a substitute for IFRS measures.

<u>Core results</u>

Alcon core results, including core operating income and core net income, exclude all amortization and impairment charges of intangible assets, excluding software, product discontinuation charges, net gains and losses on fund investments and equity securities valued at fair value through profit and loss ("FVPL"), fair value adjustments of financial assets in the form of options to acquire a company carried at FVPL, fair value remeasurements of investments in associated companies and certain acquisition related items. The following items that exceed a threshold of $10 million, are not operating expenses necessary to the operation of the business and have costs that will vary over periods are also excluded from core results: integration and divestment related income and expenses, divestment gains and losses, restructuring charges/releases and related items, legal related items, gains/losses on early extinguishment of debt or debt modifications, past service costs for post-employment benefit plans, impairments of property, plant and equipment and software, as well as income and expense items that management deems exceptional and that are or are expected to accumulate within the year to be over a $10 million threshold.

Taxes on the adjustments between IFRS and core results take into account, for each individual item included in the adjustment, the tax rate that will finally be applicable to the item based on the jurisdiction where the adjustment will finally have a tax impact. Generally, this results in amortization and impairment of intangible assets and acquisition-related restructuring and integration items having a full tax impact. There is usually a tax impact on other items, although this is not always the case for certain items such as legal settlements in certain jurisdictions.

Alcon believes that investor understanding of its performance is enhanced by disclosing core measures of performance because, since they exclude items that can vary significantly from period to period, the core measures enable a helpful comparison of business performance across periods. For this same reason, Alcon uses these core measures in addition to IFRS and other measures as important factors in assessing its performance.

A limitation of the core measures is that they provide a view of Alcon operations without including all events during a period, such as the effects of an acquisition, divestment, or amortization/impairments of purchased intangible assets and restructurings.

<u>Constant currency</u>

Changes in the relative values of non-US currencies to the US dollar can affect Alcon's financial results and financial position. To provide additional information that may be useful to investors, including changes in sales volume, we present information about changes in our net sales and various values relating to operating and net income that are adjusted for such foreign currency effects.

Constant currency calculations have the goal of eliminating two exchange rate effects so that an estimate can be made of underlying changes in the Consolidated Income Statement excluding:

• the impact of translating the income statements of consolidated entities from their non-US dollar functional currencies to the US dollar; and

------

• the impact of exchange rate movements on the major transactions of consolidated entities performed in currencies other than their functional currency.

Alcon calculates constant currency measures by translating the current year's foreign currency values for sales and other income statement items into US dollars, using the average exchange rates from the historical comparative period and comparing them to the values from the historical comparative period in US dollars.

<u>EBITDA</u>

Alcon defines earnings before interest, tax, depreciation and amortization ("EBITDA") as net income excluding income taxes, depreciation of property, plant and equipment (including any related impairment charges), depreciation of right-of-use assets, amortization of intangible assets (including any related impairment charges), interest expense and other financial income and expense. Alcon management primarily uses EBITDA together with net (debt)/liquidity to monitor leverage associated with financial debts.

<u>Free cash flow</u>

Alcon defines free cash flow as net cash flows from operating activities less cash flow associated with the purchase or sale of property, plant and equipment. Free cash flow is presented as additional information because Alcon management believes it is a useful supplemental indicator of Alcon's ability to operate without reliance on additional borrowing or use of existing cash. Free cash flow is not intended to be a substitute measure for net cash flows from operating activities as determined under IFRS.

<u>Net (debt)/liquidity</u>

Alcon defines net (debt)/liquidity as current and non-current financial debt less cash and cash equivalents, current investments, including time deposits, and derivative financial instruments. Net (debt)/liquidity is presented as additional information because management believes it is a useful supplemental indicator of Alcon's ability to pay dividends, to meet financial commitments and to invest in new strategic opportunities, including strengthening its balance sheet.

<u>Growth rate and margin calculations</u>

For ease of understanding, Alcon uses a sign convention for its growth rates such that a reduction in operating expenses or losses compared to the prior year is shown as a positive growth.

Gross margins, core gross margins, operating income margins and core operating income margins are calculated based upon net sales unless otherwise noted.

<u>Reconciliation of guidance for forward-looking non-IFRS measures</u>

The forward-looking guidance included in this press release cannot be reconciled to the comparable IFRS measures without unreasonable efforts, because we are not able to predict with reasonable certainty the ultimate amount or nature of exceptional items in the fiscal year. These items are uncertain, depend on many factors and could have a material impact on our IFRS results for the guidance period.

------

**Financial tables**

**Net sales by region** 

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** |
|<br>($ millions unless indicated otherwise) | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
| United States | 1193 | 44% | 1109 | 45% | 4657 | 45% | 4511 | 46% |
| International | 1509 | 56% | 1368 | 55% | 5662 | 55% | 5325 | 54% |
| **Net sales** | **2702** | **100%** | **2477** | **100%** | **10319** | **100%** | **9836** | **100%** |

---

**Consolidated Income Statement (unaudited)** 

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** |
|<br>($ millions except earnings per share) | **2025** | **2024** | **2025** | **2024** |
| **Net sales** | **2702** | **2477** | **10319** | **9836** |
| Other revenues | 16 | 25 | 82 | 75 |
| **Net sales and other revenues** | **2718** | **2502** | **10401** | **9911** |
| Cost of net sales | (1189) | (1093) | (4592) | (4328) |
| Cost of other revenues | (13) | (24) | (64) | (71) |
| **Gross profit** | **1516** | **1385** | **5745** | **5512** |
| Selling, general & administration | (901) | (802) | (3449) | (3250) |
| Research & development | (273) | (232) | (990) | (876) |
| Other income | 5 | 61 | 169 | 77 |
| Other expense | (34) | (17) | (115) | (50) |
| **Operating income** | **313** | **395** | **1360** | **1413** |
| Interest expense | (53) | (48) | (204) | (192) |
| Other financial income & expense | 6 | 9 | 22 | 43 |
| Share of (loss) from associated companies | (2) | (7) | (18) | (8) |
| **Income before taxes** | **264** | **349** | **1160** | **1256** |
| Taxes | (47) | (65) | (180) | (238) |
| **Net income** | **217** | **284** | **980** | **1018** |
| *Net income attributable to:* |  |  |  |  |
| &nbsp;&nbsp;*Shareholders of Alcon Inc.* | 217 | 284 | 980 | 1018 |
| &nbsp;&nbsp;*Non-controlling interests* |  |  |  |  |
| Earnings per share ($)<sup>(1)</sup> | Earnings per share ($)<sup>(1)</sup> | Earnings per share ($)<sup>(1)</sup> | Earnings per share ($)<sup>(1)</sup> | Earnings per share ($)<sup>(1)</sup> |
| Basic | 0.44 | 0.57 | 1.99 | 2.06 |
| Diluted | 0.44 | 0.57 | 1.98 | 2.05 |
| Weighted average number of shares outstanding (millions) | Weighted average number of shares outstanding (millions) | Weighted average number of shares outstanding (millions) | Weighted average number of shares outstanding (millions) | Weighted average number of shares outstanding (millions) |
| Basic | 489.3 | 494.7 | 493.2 | 494.4 |
| Diluted | 492.3 | 498.1 | 496.2 | 497.5 |

---

(1) Earnings per share is calculated on the amount of net income attributable to shareholders of Alcon Inc.

------

**Segment contribution** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** |
| | | | **Change %** | | | **Change %** |
|<br>($ millions unless indicated otherwise) | **2025** | **2024** | $**cc**<sup>(1)</sup><br>**(non-IFRS measure)** | **2025** | **2024** | $**cc**<sup>(1)</sup><br>**(non-IFRS measure)** |
| Surgical segment contribution | 389 | 347 | 8 | 1460 | 1467 | (1) |
| &nbsp;&nbsp;*As % of net sales* | *25.2* | *24.4* |  | *25.4* | *26.6* |  |
| Vision Care segment contribution | 235 | 260 | (14) | 981 | 962 | 1 |
| &nbsp;&nbsp;*As % of net sales* | *20.3* | *24.7* |  | *21.5* | *22.3* |  |
| Not allocated to segments | (311) | (212) | (47) | (1081) | (1016) | (6) |
| **Operating income** | **313** | **395** | **(27)** | **1360** | **1413** | **(5)** |
| Core adjustments (non-IFRS measure)<sup>(1)</sup> | 201 | 103 |  | 679 | 614 |  |
| **Core operating income (non-IFRS measure)**<sup>(1)</sup> | **514** | **498** | **(2)** | **2039** | **2027** | **—** |

---

(1)Core results and constant currency are non-IFRS measures. Refer to the 'Non-IFRS measures as defined by the Company' section for additional information and to the 'Reconciliation of IFRS results to core results (non-IFRS measure)' section for reconciliation tables.

**Operating income**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** |
| | | | **Change %** | | | **Change %** |
|<br>($ millions unless indicated otherwise) | **2025** | **2024** | $**cc**<sup>(1)</sup><br>**(non-IFRS measure)** | **2025** | **2024** | $**cc**<sup>(1)</sup><br>**(non-IFRS measure)** |
| Cost of net sales | (1189) | (1093) | (7) | (4592) | (4328) | (6) |
| **Gross profit** | **1516** | **1385** | **6** | **5745** | **5512** | **3** |
| *Gross margin (%)* | *56.1* | *55.9* |  | *55.7* | *56.0* |  |
| Selling, general & administration | (901) | (802) | (10) | (3449) | (3250) | (5) |
| Research & development | (273) | (232) | (16) | (990) | (876) | (12) |
| Other income | 5 | 61 | (92) | 169 | 77 | 120 |
| Other expense | (34) | (17) | (106) | (115) | (50) | (133) |
| **Operating income** | **313** | **395** | **(27)** | **1360** | **1413** | **(5)** |
| *Operating margin (%)* | *11.6* | *15.9* |  | *13.2* | *14.4* |  |
| **Core results (non-IFRS measure)**<sup>(1)</sup> |  |  |  |  |  |  |
| Core gross profit | 1688 | 1552 | 6 | 6471 | 6177 | 4 |
| *Core gross margin (%)* | *62.5* | *62.7* |  | *62.7* | *62.8* |  |
| Core operating income | 514 | 498 | (2) | 2039 | 2027 |  |
| *Core operating margin (%)* | *19.0* | *20.1* |  | *19.8* | *20.6* |  |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Core results and constant currency are non-IFRS measures. Refer to the 'Non-IFRS measures as defined by the Company' section for additional information and to the 'Reconciliation of IFRS results to core results (non-IFRS measure)' section for reconciliation tables.

------

**Non-operating income & expense** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** |
| | | | **Change %** | | | **Change %** |
|<br>($ millions unless indicated otherwise) | **2025** | **2024** | $**cc**<sup>(1)</sup><br>**(non-IFRS measure)** | **2025** | **2024** | $**cc**<sup>(1)</sup><br>**(non-IFRS measure)** |
| **Operating income** | **313** | **395** | **(27)** | **1360** | **1413** | **(5)** |
| Interest expense | (53) | (48) | (8) | (204) | (192) | (6) |
| Other financial income & expense | 6 | 9 | (32) | 22 | 43 | (49) |
| Share of (loss) from associated companies | (2) | (7) | 80 | (18) | (8) | (126) |
| **Income before taxes** | **264** | **349** | **(31)** | **1160** | **1256** | **(9)** |
| Taxes | (47) | (65) | 33 | (180) | (238) | 26 |
| **Net income** | **217** | **284** | **(31)** | **980** | **1018** | **(5)** |
| *Net income attributable to:* |  |  |  |  |  |  |
| &nbsp;&nbsp;*Shareholders of Alcon Inc.* | 217 | 284 | (31) | 980 | 1018 | (5) |
| &nbsp;&nbsp;*Non-controlling interests* |  |  |  |  |  |  |
| Basic earnings per share ($)<sup>(2)</sup> | 0.44 | 0.57 | (30) | 1.99 | 2.06 | (5) |
| Diluted earnings per share ($)<sup>(2)</sup> | 0.44 | 0.57 | (30) | 1.98 | 2.05 | (5) |
| **Core results (non-IFRS measure)**<sup>(1)</sup> |  |  |  |  |  |  |
| Core taxes | (83) | (93) | 14 | (323) | (355) | 10 |
| **Core net income** | **382** | **359** | **1** | **1521** | **1515** | **(1)** |
| *Core net income attributable to:* |  |  |  |  |  |  |
| &nbsp;&nbsp;*Shareholders of Alcon Inc.* | 382 | 359 | 1 | 1521 | 1515 | (1) |
| &nbsp;&nbsp;*Non-controlling interests* |  |  |  |  |  |  |
| Core basic earnings per share ($)<sup>(2)</sup> | 0.78 | 0.73 | 2 | 3.08 | 3.06 |  |
| Core diluted earnings per share ($)<sup>(2)</sup> | 0.78 | 0.72 | 2 | 3.07 | 3.05 |  |

---

(1)Core results and constant currency are non-IFRS measures. Refer to the 'Non-IFRS measures as defined by the Company' section for additional information and to the 'Reconciliation of IFRS results to core results (non-IFRS measure)' section for reconciliation tables.

(2)Earnings per share and core earnings per share are calculated on the amount of net income and core net income, respectively, attributable to shareholders of Alcon Inc. Per share amounts may not add across quarters due to rounding.

------

**Reconciliation of IFRS results to core results (non-IFRS measure)** 

**Three months ended December 31, 2025**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| ($ millions except earnings per share) | **IFRS<br>results** | **Amortization of certain intangible assets**<sup>(1)</sup> | **Acquisition and integration related items**<sup>(5</sup><sup>)</sup> | **Legal items**<sup>(6)</sup> | **Core results (non-IFRS measure)** |
| **Gross profit** | **1516** | **171** | **1** | **—** | **1688** |
| **Operating income** | **313** | **175** | **22** | **4** | **514** |
| **Income before taxes** | **264** | **175** | **22** | **4** | **465** |
| Taxes<sup>(9)</sup> | (47) | (31) | (4) | (1) | (83) |
| **Net income** | **217** | **144** | **18** | **3** | **382** |
| *Net income attributable to:* |  |  |  |  |  |
| &nbsp;&nbsp;*Shareholders of Alcon Inc.* | *217* | *144* | *18* | *3* | *382* |
| &nbsp;&nbsp;*Non-controlling interests* | *—* | *—* | *—* | *—* | *—* |
| Basic earnings per share ($)<sup>(10)</sup> | 0.44 |  |  |  | 0.78 |
| Diluted earnings per share ($)<sup>(10)</sup> | 0.44 |  |  |  | 0.78 |
| Basic - weighted average shares outstanding (millions)<sup>(10)</sup> | 489.3 |  |  |  | 489.3 |
| Diluted - weighted average shares outstanding (millions)<sup>(10)</sup> | 492.3 |  |  |  | 492.3 |

---

Refer to the associated explanatory footnotes at the end of the 'Reconciliation of IFRS results to core results (non-IFRS measure)' tables.

**Three months ended December 31, 2024**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| ($ millions except earnings per share) | **IFRS<br>results** | **Amortization of certain intangible assets**<sup>(1)</sup> | **Divestment of product rights**<sup>(3)</sup> | **Other items**<sup>(8)</sup> | **Core results (non-IFRS measure)** |
| **Gross profit** | **1385** | **167** | **—** | **—** | **1552** |
| **Operating income** | **395** | **169** | **(57)** | **(9)** | **498** |
| **Income before taxes** | **349** | **169** | **(57)** | **(9)** | **452** |
| Taxes<sup>(9)</sup> | (65) | (30) | 2 |  | (93) |
| **Net income** | **284** | **139** | **(55)** | **(9)** | **359** |
| *Net income attributable to:* |  |  |  |  |  |
| &nbsp;&nbsp;*Shareholders of Alcon Inc.* | *284* | *139* | *(55)* | *(9)* | *359* |
| &nbsp;&nbsp;*Non-controlling interests* | *—* | *—* | *—* | *—* | *—* |
| Basic earnings per share ($)<sup>(10)</sup> | 0.57 |  |  |  | 0.73 |
| Diluted earnings per share ($)<sup>(10)</sup> | 0.57 |  |  |  | 0.72 |
| Basic - weighted average shares outstanding (millions)<sup>(10)</sup> | 494.7 |  |  |  | 494.7 |
| Diluted - weighted average shares outstanding (millions)<sup>(10)</sup> | 498.1 |  |  |  | 498.1 |

---

Refer to the associated explanatory footnotes at the end of the 'Reconciliation of IFRS results to core results (non-IFRS measure)' tables.

------

**Twelve months ended December 31, 2025**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| ($ millions except earnings per share) | **IFRS<br>results** | **Amortization of certain intangible assets**<sup>(1)</sup> | **Impairments**<sup>(2)</sup> | **Gains on investments in associated companies**<sup>(4)</sup> | **Acquisition and integration related items**<sup>(5)</sup> | **Legal items**<sup>(6)</sup> | **Product discontinuation**<sup>(7)</sup> | **Other <br>items**<sup>(8)</sup> | **Core results (non-IFRS measure)** |
| **Gross profit** | **5745** | **681** | **—** | **—** | **1** | **—** | **44** | **—** | **6471** |
| **Operating income** | **1360** | **696** | **2** | **(142)** | **58** | **21** | **44** | **—** | **2039** |
| **Income before taxes** | **1160** | **696** | **2** | **(142)** | **58** | **21** | **44** | **5** | **1844** |
| Taxes<sup>(9)</sup> | (180) | (124) |  |  | (12) | (5) | (10) | 8 | (323) |
| **Net income** | **980** | **572** | **2** | **(142)** | **46** | **16** | **34** | **13** | **1521** |
| *Net income attributable to:* |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;*Shareholders of Alcon Inc.* | *980* | *572* | *2* | *(142)* | *46* | *16* | *34* | *13* | *1521* |
| &nbsp;&nbsp;*Non-controlling interests* | *—* | *—* | *—* | *—* | *—* | *—* | *—* | *—* | *—* |
| Basic earnings per share ($)<sup>(10)</sup> | 1.99 |  |  |  |  |  |  |  | 3.08 |
| Diluted earnings per share ($)<sup>(10)</sup> | 1.98 |  |  |  |  |  |  |  | 3.07 |
| Basic - weighted average shares outstanding (millions)<sup>(10)</sup> | 493.2 |  |  |  |  |  |  |  | 493.2 |
| Diluted - weighted average shares outstanding (millions)<sup>(10)</sup> | 496.2 |  |  |  |  |  |  |  | 496.2 |

---

Refer to the associated explanatory footnotes at the end of the 'Reconciliation of IFRS results to core results (non-IFRS measure)' tables.

**Twelve months ended December 31, 2024**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| ($ millions except earnings per share) | **IFRS<br>results** | **Amortization of certain intangible assets**<sup>(1)</sup> | **Impairments**<sup>(2)</sup> | **Divestment of product rights**<sup>(3)</sup> | **Acquisition and integration related items**<sup>(5)</sup> | **Other <br>items**<sup>(8)</sup> | **Core results (non-IFRS measure)** |
| **Gross profit** | **5512** | **662** | **—** | **—** | **3** | **—** | **6177** |
| **Operating income** | **1413** | **667** | **9** | **(57)** | **3** | **(8)** | **2027** |
| **Income before taxes** | **1256** | **667** | **9** | **(57)** | **3** | **(8)** | **1870** |
| Taxes<sup>(9)</sup> | (238) | (119) |  | 2 | (1) | 1 | (355) |
| **Net income** | **1018** | **548** | **9** | **(55)** | **2** | **(7)** | **1515** |
| *Net income attributable to:* |  |  |  |  |  |  |  |
| &nbsp;&nbsp;*Shareholders of Alcon Inc.* | *1018* | *548* | *9* | *(55)* | *2* | *(7)* | *1515* |
| &nbsp;&nbsp;*Non-controlling interests* | *—* | *—* | *—* | *—* | *—* | *—* | *—* |
| Basic earnings per share ($)<sup>(10)</sup> | 2.06 |  |  |  |  |  | 3.06 |
| Diluted earnings per share ($)<sup>(10)</sup> | 2.05 |  |  |  |  |  | 3.05 |
| Basic - weighted average shares outstanding (millions)<sup>(10)</sup> | 494.4 |  |  |  |  |  | 494.4 |
| Diluted - weighted average shares outstanding (millions)<sup>(10)</sup> | 497.5 |  |  |  |  |  | 497.5 |

---

Refer to the associated explanatory footnotes at the end of the 'Reconciliation of IFRS results to core results (non-IFRS measure)' tables.

------

**Explanatory footnotes to IFRS to core reconciliation tables** 

(1)Includes amortization for all intangible assets other than software.

(2)&nbsp;&nbsp;&nbsp;&nbsp;Includes impairment charges related to intangible assets.

(3)&nbsp;&nbsp;&nbsp;&nbsp;For the three and twelve months ended December 31, 2024, includes a net gain related to the divestment of certain product rights in China.

(4)&nbsp;&nbsp;&nbsp;&nbsp;For the twelve months ended December 31, 2025, includes gains on fair value remeasurements of investments in associated companies.

(5)&nbsp;&nbsp;&nbsp;&nbsp;For the three months ended December 31, 2025, Gross profit includes the amortization of inventory fair value adjustments related to an acquisition. Operating income also includes $18 million of direct acquisition costs and $3 million of integration related costs related to acquisitions. Acquisition costs primarily include third party professional services for legal fees. Integration related costs include third party professional services of $2 million and accelerated equity-based compensation expense of $1 million.

For the twelve months ended December 31, 2025, Gross profit includes the amortization of inventory fair value adjustments related to an acquisition. Operating income also includes $46 million of direct acquisition costs and $11 million of integration related costs related to acquisitions. Acquisition costs primarily include third party professional services for legal, banker, due diligence and accounting fees. Integration related costs include accelerated equity-based compensation expense of $4 million, third party professional services of $4 million and severance of $3 million.

For the twelve months ended December 31, 2024, Gross profit includes the amortization of inventory fair value adjustments related to an acquisition.

(6)&nbsp;&nbsp;&nbsp;&nbsp;For the three and twelve months ended December 31, 2025, includes provisions for legal matters.

(7)&nbsp;&nbsp;&nbsp;&nbsp;For the twelve months ended December 31, 2025, includes charges related to the discontinued commercialization of a product in the Vision Care reportable segment, including $43 million for the full impairment of the intangible asset and $1 million in related costs, primarily related to inventory provisions.

(8)&nbsp;&nbsp;&nbsp;&nbsp;For the three months ended December 31, 2024, Operating income primarily includes fair value adjustments to contingent consideration liabilities, partially offset by the amortization of option rights.

For the twelve months ended December 31, 2025, Income before taxes includes core adjustments recognized for Aurion in Share of (loss) from associated companies. The expenses were incurred upon change in control from Alcon's acquisition of a majority interest in Aurion and include accelerated equity-based compensation expense of $2 million, third party professional services of $2 million for legal and accounting fees and third party bank fees of $1 million.

For the twelve months ended December 31, 2024, Operating income includes fair value adjustments to contingent consideration liabilities and fair value adjustments of financial assets, partially offset by the amortization of option rights.

(9)&nbsp;&nbsp;&nbsp;&nbsp;For the three months ended December 31, 2025, tax associated with operating income core adjustments of $201 million totaled $36 million with an average tax rate of 17.9%.

For the three months ended December 31, 2024, tax associated with operating income core adjustments of $103 million totaled $28 million with an average tax rate of 27.2%.

For the twelve months ended December 31, 2025, total tax adjustments of $143 million include tax associated with operating income core adjustments, partially offset by discrete tax items. Operating income core adjustments totaled $679 million. Excluding the non-taxable gain of $136 million on fair value remeasurement of Alcon's investment in Aurion, core adjustments to operating income totaled $815 million. The associated tax effect amounted to $151 million with an average tax rate of 18.5%. Core tax adjustments for discrete tax items totaled $8 million.

For the twelve months ended December 31, 2024, tax associated with operating income core adjustments of $614 million totaled $117 million with an average tax rate of 19.1%.

(10)&nbsp;&nbsp;&nbsp;&nbsp;Core basic earnings per share is calculated using core net income attributable to shareholders of Alcon Inc. and the weighted-average shares of common stock outstanding during the period. Core diluted earnings per share also contemplate dilutive shares associated with unvested equity-based awards as described in Note 5 to the Condensed Consolidated Interim Financial Statements.

------

**EBITDA (non-IFRS measure)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** |
|<br>($ millions) | **2025** | **2024** | **2025** | **2024** |
| **Net income** | **217** | **284** | **980** | **1018** |
| Taxes | 47 | 65 | 180 | 238 |
| Depreciation of property, plant & equipment | 110 | 100 | 417 | 392 |
| Depreciation of right-of-use assets | 22 | 21 | 89 | 83 |
| Amortization of intangible assets | 200 | 188 | 784 | 743 |
| Impairments of property, plant & equipment and intangible assets |  | 1 | 45 | 10 |
| Interest expense | 53 | 48 | 204 | 192 |
| Other financial income & expense | (6) | (9) | (22) | (43) |
| **EBITDA** | **643** | **698** | **2677** | **2633** |

---

**Cash flow and net (debt)/liquidity (non-IFRS measure)**

---

| | | |
|:---|:---|:---|
| | **Twelve months ended December 31** | **Twelve months ended December 31** |
|<br>($ millions) | **2025** | **2024** |
| Net cash flows from operating activities | 2271 | 2077 |
| Net cash flows used in investing activities | (1344) | (1167) |
| Net cash flows used in financing activities | (1119) | (322) |
| Effect of exchange rate changes on cash and cash equivalents | 43 | (6) |
| **Net change in cash and cash equivalents** | **(149)** | **582** |
| Change in derivative financial instrument assets | (7) | 10 |
| Change in time deposits with original maturity greater than three months | (73) | 153 |
| Change in current and non-current financial debts | (94) | 96 |
| **Change in net (debt)** | **(323)** | **841** |
| Net (debt) at January 1 | (2802) | (3643) |
| **Net (debt) at December 31** | **(3125)** | **(2802)** |

---

------

**Net (debt)/liquidity (non-IFRS measure)**

---

| | | |
|:---|:---|:---|
| ($ millions) | **At December 31, 2025** | **At December 31, 2024** |
| Current financial debt | (575) | (105) |
| Non-current financial debt | (4162) | (4538) |
| **Total financial debt** | **(4737)** | **(4643)** |
| **Less liquidity:** |  |  |
| Cash and cash equivalents | 1527 | 1676 |
| Time deposits with original maturity greater than three months | 80 | 153 |
| Derivative financial instruments | 5 | 12 |
| **Total liquidity** | **1612** | **1841** |
| **Net (debt)** | **(3125)** | **(2802)** |

---

**Free cash flow (non-IFRS measure)**

The following is a summary of free cash flow for the twelve months ended December 31, 2025 and 2024, together with a reconciliation to net cash flows from operating activities, the most directly comparable IFRS measure:

---

| | | |
|:---|:---|:---|
| | **Twelve months ended December 31** | **Twelve months ended December 31** |
|<br>($ millions) | **2025** | **2024** |
| **Net cash flows from operating activities** | **2271** | **2077** |
| Purchase of property, plant & equipment | (543) | (473) |
| Proceeds from sale of property, plant & equipment | 5 |  |
| **Free cash flow** | **1733** | **1604** |

---

------

**About Alcon**

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at <u>www.alcon.com</u>.

**Connect with us on** ![facebooklogoa.gif](facebooklogoa.gif)![linkedinlogoa.gif](linkedinlogoa.gif)

**<u>Investor Relations</u>**

Daniel Cravens

Allen Trang

+ 41 589 112 110 (Geneva)

+ 1 817 615 2789 (Fort Worth)

<u>investor.relations@alcon.com</u>

**<u>Media Relations</u>**

Steven Smith

+ 41 589 112 111 (Geneva)

+ 1 817 551 8057 (Fort Worth)

<u>globalmedia.relations@alcon.com</u>

## Exhibit 99.2

**ALCON INC. INTERIM FINANCIAL REPORT**

---

| | |
|:---|:---|
| **INDEX** | **Page** |
| Operating Performance | <u>[2](#i7b3d2e5b1af248a7bfca4d4538f7f390_4)</u> |
| Liquidity and Capital Resources | <u>[10](#i7b3d2e5b1af248a7bfca4d4538f7f390_37)</u> |
| Condensed Consolidated Interim Financial Statements of Alcon Inc. (unaudited) | Condensed Consolidated Interim Financial Statements of Alcon Inc. (unaudited) |
| &nbsp;&nbsp;&nbsp;&nbsp;Consolidated Income Statement | <u>[14](#i7b3d2e5b1af248a7bfca4d4538f7f390_52)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;Consolidated Statement of Comprehensive Income | <u>[15](#i7b3d2e5b1af248a7bfca4d4538f7f390_55)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;Consolidated Balance Sheet | <u>[16](#i7b3d2e5b1af248a7bfca4d4538f7f390_58)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;Consolidated Statement of Changes in Equity | <u>[17](#i7b3d2e5b1af248a7bfca4d4538f7f390_61)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;Consolidated Statement of Cash Flows | <u>[18](#i7b3d2e5b1af248a7bfca4d4538f7f390_64)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;Notes to Condensed Consolidated Interim Financial Statements of Alcon Inc. | <u>[19](#i7b3d2e5b1af248a7bfca4d4538f7f390_67)</u> |
| Disclaimer | <u>[40](#i7b3d2e5b1af248a7bfca4d4538f7f390_142)</u> |

---

------

**OPERATING PERFORMANCE**

Key figures

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** |
|<br>($ millions unless indicated otherwise) | **2025** | **2024** | **Change %** | **2025** | **2024** | **Change %** |
| Net sales | 2702 | 2477 | 9 | 10319 | 9836 | 5 |
| Gross profit | 1516 | 1385 | 9 | 5745 | 5512 | 4 |
| Operating income | 313 | 395 | (21) | 1360 | 1413 | (4) |
| *Operating margin (%)* | *11.6* | *15.9* |  | *13.2* | *14.4* |  |
| **Net income** | **217** | **284** | **(24)** | **980** | **1018** | **(4)** |
| *Net income attributable to:* |  |  |  |  |  |  |
| &nbsp;&nbsp;*Shareholders of Alcon Inc.* | 217 | 284 | (24) | 980 | 1018 | (4) |
| &nbsp;&nbsp;*Non-controlling interests* |  |  |  |  |  |  |
| Basic earnings per share ($)<sup>(1)</sup> | 0.44 | 0.57 | (23) | 1.99 | 2.06 | (3) |
| Diluted earnings per share ($)<sup>(1)</sup> | 0.44 | 0.57 | (23) | 1.98 | 2.05 | (3) |

---

(1)Earnings per share is calculated on the amount of net income attributable to shareholders of Alcon Inc. Per share amounts may not add across quarters due to rounding.

------

Net sales by segment

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** |
|<br>($ millions unless indicated otherwise) | **2025** | **2024** | **Change %** | **2025** | **2024** | **Change %** |
| **Surgical** |  |  |  |  |  |  |
| Implantables | 474 | 456 | 4 | 1782 | 1775 |  |
| Consumables | 794 | 738 | 8 | 3028 | 2861 | 6 |
| Equipment/other | 277 | 229 | 21 | 941 | 886 | 6 |
| **Total Surgical** | **1545** | **1423** | **9** | **5751** | **5522** | **4** |
| **Vision Care** |  |  |  |  |  |  |
| Contact lenses | 683 | 638 | 7 | 2770 | 2609 | 6 |
| Ocular health | 474 | 416 | 14 | 1798 | 1705 | 5 |
| **Total Vision Care** | **1157** | **1054** | **10** | **4568** | **4314** | **6** |
| **Net sales** | **2702** | **2477** | **9** | **10319** | **9836** | **5** |

---

Fourth quarter

Surgical

Surgical net sales were $1.5 billion, an increase of 9%, including favorable currency impacts of 3%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Implantables net sales were $474 million, an increase of 4%, including favorable currency impacts of 2%. This growth reflects strong performance by *PanOptix* Pro in the US, partially offset by continued competitive pressures, particularly in international markets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consumables net sales were $794 million, an increase of 8%, including favorable currency impacts of 3%. Growth was driven by cataract and vitreoretinal procedural growth, as well as price increases.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Equipment/other net sales were $277 million, an increase of 21%, including favorable currency impacts of 3%. This growth was led by recent equipment launches, including the *Unity* platform.

Vision Care

Vision Care net sales were $1.2 billion, an increase of 10%, including favorable currency impacts of 3%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Contact lenses net sales were $683 million, an increase of 7%, including favorable currency impacts of 3%. This growth was led by price increases and product innovation, partially offset by declines in legacy products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Ocular health net sales were $474 million, an increase of 14%, including favorable currency impacts of 2%. Growth was led by our portfolio of dry eye products, including *Tryptyr* and *Systane*.

Full year

Surgical

Surgical net sales were $5.8 billion, an increase of 4%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Implantables net sales were $1.8 billion, in line with the prior year period. These results reflect the launch of *PanOptix* Pro in the US, as well as soft market conditions and competitive pressures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consumables net sales were $3.0 billion, an increase of 6%, including favorable currency impacts of 1%. Growth was driven by vitreoretinal procedural growth and price increases, partially offset by soft cataract market conditions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Equipment/other net sales were $941 million, an increase of 6%, as sales of recently launched equipment, including *Unity* VCS, were partially offset by declines in legacy equipment.

------

Vision Care

Vision Care net sales were $4.6 billion, an increase of 6%, including favorable currency impacts of 1%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Contact lenses net sales were $2.8 billion, an increase of 6%, including favorable currency impacts of 1%. Growth was primarily driven by price increases and product innovation, partially offset by declines in legacy products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Ocular health net sales were $1.8 billion, an increase of 5%, including unfavorable currency impacts of 1%. Growth was led by our portfolio of dry eye products, including *Tryptyr* and *Systane*. The prior year period included sales of certain eye drops in China which were divested and out-licensed in late 2024.

------

Operating income

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** |
|<br>($ millions unless indicated otherwise) | **2025** | **2024** | **Change %** | **2025** | **2024** | **Change %** |
| Cost of net sales | (1189) | (1093) | (9) | (4592) | (4328) | (6) |
| **Gross profit** | **1516** | **1385** | **9** | **5745** | **5512** | **4** |
| *Gross margin (%)* | *56.1* | *55.9* |  | *55.7* | *56.0* |  |
| Selling, general & administration | (901) | (802) | (12) | (3449) | (3250) | (6) |
| Research & development | (273) | (232) | (18) | (990) | (876) | (13) |
| Other income | 5 | 61 | (92) | 169 | 77 | 119 |
| Other expense | (34) | (17) | (100) | (115) | (50) | (130) |
| **Operating income** | **313** | **395** | **(21)** | **1360** | **1413** | **(4)** |
| *Operating margin (%)* | *11.6* | *15.9* |  | *13.2* | *14.4* |  |

---

Fourth quarter

Operating income was $313 million (-21%), compared to $395 million in the prior year period. Operating margin decreased 4.3 percentage points. The current year period included sales and marketing investments behind new product launches, increased investment in research and development, including from recent acquisitions, incremental tariffs and acquisition and integration related items, partially offset by favorability from annual incentive compensation, price increases and a positive 0.8 percentage point impact from currency. The prior year period included a net gain related to the divestment of certain product rights in China.

Full year

Operating income was $1.4 billion (-4%), down slightly from the prior year period. Operating margin decreased 1.2 percentage points. The current year period included sales and marketing investments behind new product launches, increased investment in research and development, including from recent acquisitions, incremental tariffs, acquisition and integration related items and product discontinuation charges in Vision Care. The decline in operating margin was partially offset by price increases, fair value remeasurements of investments in associated companies, favorability from annual incentive compensation and a positive 0.1 percentage point impact from currency. The prior year period included a net gain related to the divestment of certain product rights in China.

------

Segment contribution

For additional information regarding segment contribution, please refer to Note 3 to the Condensed Consolidated Interim Financial Statements.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** |
|<br>($ millions unless indicated otherwise) | **2025** | **2024** | **Change %** | **2025** | **2024** | **Change %** |
| Surgical segment contribution | 389 | 347 | 12 | 1460 | 1467 |  |
| &nbsp;&nbsp;*As % of net sales* | *25.2* | *24.4* |  | *25.4* | *26.6* |  |
| Vision Care segment contribution | 235 | 260 | (10) | 981 | 962 | 2 |
| &nbsp;&nbsp;*As % of net sales* | *20.3* | *24.7* |  | *21.5* | *22.3* |  |
| Not allocated to segments | (311) | (212) | (47) | (1081) | (1016) | (6) |
| **Operating income** | **313** | **395** | **(21)** | **1360** | **1413** | **(4)** |

---

Fourth quarter

Surgical

Surgical segment contribution was $389 million (+12%), compared to $347 million in the prior year period. Segment contribution margin increased 0.8 percentage points, primarily driven by operating leverage from higher sales, favorability from annual incentive compensation and a positive 0.4 percentage point impact from currency, partially offset by sales and marketing investments behind new product launches and incremental tariffs.

Vision Care

Vision Care segment contribution was $235 million (-10%), compared to $260 million in the prior year period. Segment contribution margin decreased 4.4 percentage points, primarily due to increased investment in research and development, including from a recent acquisition, sales and marketing investments behind new product launches and incremental tariffs. The decline in segment contribution margin was partially offset by price increases, favorability from annual incentive compensation and a positive 0.4 percentage point impact from currency.

Not allocated to segments

Operating loss not allocated to segments totaled $311 million (-47%), compared to $212 million in the prior year period. The current year period included $22 million of acquisition and integration items. The prior year period included a $57 million net gain related to the divestment of certain product rights in China.

Full year

Surgical

Surgical segment contribution was $1.5 billion (0%), in line with the prior year period. Segment contribution margin decreased 1.2 percentage points, primarily due to higher inventory-related costs, including incremental tariffs, and sales and marketing investments behind new product launches, partially offset by favorability from annual incentive compensation and price increases.

Vision Care

Vision Care segment contribution was $981 million (+2%), compared to $962 million in the prior year period. Segment contribution margin decreased 0.8 percentage points. The current year period included increased investment in research and development, including from a recent acquisition, sales and marketing investments behind new product launches and incremental tariffs, partially offset by price increases, manufacturing efficiencies, favorability from annual incentive compensation and a positive 0.1 percentage point impact from currency. The prior year period was impacted by inventory provisions due to a supplier-related quality issue.

------

Not allocated to segments

Operating loss not allocated to segments totaled $1.1 billion (-6%), compared to $1.0 billion in the prior year period. The current year period included $58 million of acquisition and integration items, $44 million of product discontinuation charges, higher amortization of intangible assets and legal items, partially offset by gains of $142 million on fair value remeasurements of investments in associated companies. The prior year period included a $57 million net gain related to the divestment of certain product rights in China.

------

Non-operating income & expense

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** |
|<br>($ millions unless indicated otherwise) | **2025** | **2024** | **Change %** | **2025** | **2024** | **Change %** |
| **Operating income** | **313** | **395** | **(21)** | **1360** | **1413** | **(4)** |
| Interest expense | (53) | (48) | (10) | (204) | (192) | (6) |
| Other financial income & expense | 6 | 9 | (33) | 22 | 43 | (49) |
| Share of (loss) from associated companies | (2) | (7) | 71 | (18) | (8) | (125) |
| **Income before taxes** | **264** | **349** | **(24)** | **1160** | **1256** | **(8)** |
| Taxes | (47) | (65) | 28 | (180) | (238) | 24 |
| **Net income** | **217** | **284** | **(24)** | **980** | **1018** | **(4)** |
| *Net income attributable to:* |  |  |  |  |  |  |
| &nbsp;&nbsp;*Shareholders of Alcon Inc.* | 217 | 284 | (24) | 980 | 1018 | (4) |
| &nbsp;&nbsp;*Non-controlling interests* |  |  |  |  |  |  |
| Basic earnings per share ($)<sup>(1)</sup> | 0.44 | 0.57 | (23) | 1.99 | 2.06 | (3) |
| Diluted earnings per share ($)<sup>(1)</sup> | 0.44 | 0.57 | (23) | 1.98 | 2.05 | (3) |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Earnings per share is calculated on the amount of net income attributable to shareholders of Alcon Inc. Per share amounts may not add across quarters due to rounding.

Fourth quarter

Interest expense

Interest expense was $53 million, compared to $48 million in the prior year period, primarily driven by higher interest expense from discounting of long-term contingent consideration liabilities.

Other financial income & expense

Other financial income & expense was a net benefit of $6 million, compared to $9 million in the prior year period, primarily driven by lower interest income, partially offset by a decrease in foreign currency exchange losses.

Share of (loss) from associated companies

Share of (loss) from associated companies was $2 million, compared to $7 million in the prior year period, following a decrease in Alcon's investment in associated companies compared to the prior year period.

Taxes

Tax expense was $47 million, compared to $65 million in the prior year period. The average tax rate was 17.8%, compared to 18.6% in the prior year period, primarily driven by a more favorable mix of pre-tax income/(loss) across geographical tax jurisdictions and higher discrete tax benefits in the current year period.

Net income and earnings per share

Net income attributable to shareholders of Alcon Inc. was $217 million, compared to $284 million in the prior year period, primarily due to lower operating income. The associated basic and diluted earnings per share were $0.44, compared to basic and diluted earnings per share of $0.57 in the prior year period.

Full year

Interest expense

Interest expense was $204 million, compared to $192 million in the prior year period, primarily driven by higher interest expense from discounting of long-term contingent consideration liabilities and higher interest expense on lease liabilities.

Other financial income & expense

Other financial income & expense was a net benefit of $22 million, compared to $43 million in the prior year period, primarily driven by lower interest income and an increase in foreign currency exchange losses.

------

Share of (loss) from associated companies

Share of (loss) from associated companies was $18 million, compared to $8 million in the prior year period, reflecting Alcon's investment in associated companies during the year.

Taxes

Tax expense was $180 million, compared to $238 million in the prior year period. The average tax rate was 15.5%, compared to 18.9% in the prior year period. The decrease in average tax rate is primarily driven by a non-taxable gain on the fair value remeasurement of an investment in an associated company and higher discrete tax benefits in the current year period.

Net income and earnings per share

Net income was $980 million, compared to $1.0 billion in the prior year period, primarily due to lower operating income and higher non-operating income & expense, partially offset by lower tax expense. The associated basic and diluted earnings per share were $1.99 and $1.98, respectively, compared to basic and diluted earnings per share of $2.06 and $2.05, respectively, in the prior year period.

------

**LIQUIDITY AND CAPITAL RESOURCES**

Cash flow

Net cash flows from operating activities

Net cash flows from operating activities amounted to $2.3 billion in 2025, compared to $2.1 billion in the prior year period. The current year period reflects increased collections associated with higher sales, lower taxes paid due to timing of payments and deductions as well as tax refunds received, partially offset by increased payments for operating expenses, including sales and marketing investments behind new product launches, increased investment in research and development and incremental tariffs, higher payments for revenue deductions and a higher impact from changes in net working capital.

Changes in net working capital in the current year were mainly driven by an increase in inventories and an increase in trade receivables, partially offset by an increase in trade payables. The increase in inventories was primarily to meet expected upcoming demand. The increase in trade receivables was primarily driven by new receivables from higher sales outpacing collections. The increase in trade payables was primarily driven by the timing of payments and raw materials purchases.

Changes in net working capital in the prior year period were mainly driven by increases in trade receivables and inventories and the net change in other operating liabilities. The increase in trade receivables was primarily due to new receivables from higher sales outpacing collections. The increase in inventories was primarily to meet expected upcoming demand. The net change in other operating liabilities was primarily due to the impact of annual short-term incentive payments.

Net cash flows used in investing activities

Net cash flows used in investing activities amounted to $1.3 billion in 2025, compared to $1.2 billion in the prior year period. Cash outflows in the current year period primarily include the acquisition of a majority interest in Aurion Biotech, Inc. ("Aurion"), the acquisitions of LumiThera, Inc. ("LumiThera") and Cylite Pty Ltd. ("Cylite"), capital expenditures and purchases of intangible assets, primarily related to software, the purchase of a time deposit in the fourth quarter of 2025 and payments for financial assets measured at fair value through other comprehensive income ("FVOCI"), partially offset by proceeds from a time deposit which matured in February 2025. Refer to Note 12 to the Condensed Consolidated Interim Financial Statements for additional information on the Aurion, LumiThera and Cylite transactions.

Cash outflows in the prior year period primarily included capital expenditures, purchases of software and other intangible assets, investments in associated companies, purchase of time deposits, payments for financial assets measured at FVOCI, and the acquisition of BELKIN Vision Ltd. ("BELKIN"). Refer to Notes 13 and 12 to the Condensed Consolidated Interim Financial Statements for additional information on the investments in associated companies and BELKIN acquisition, respectively.

Net cash flows used in financing activities

Net cash flows used in financing activities amounted to $1.1 billion in 2025, compared to $322 million in the prior year period. Cash outflows in the current year period primarily include payments for the acquisition of treasury shares, dividends paid to shareholders of Alcon Inc., realized foreign exchange losses, lease payments and withholding taxes paid upon net settlements of equity-based compensation.

Cash outflows in the prior year period primarily included dividends paid to shareholders of Alcon Inc., lease payments, net payments related to certain local debt facilities and withholding taxes paid upon net settlements of equity-based compensation.

------

Balance sheet

Assets

Total non-current assets were $25.1 billion as of December 31, 2025, an increase of $1.1 billion when compared to $24.0 billion as of December 31, 2024. Intangible assets other than goodwill and Goodwill increased $419 million and $310 million, respectively, primarily due to the acquisition of a majority interest in Aurion, the acquisitions of LumiThera and Cylite and additions of software and other intangible assets, partially offset by recurring amortization and asset impairments. Property, plant and equipment increased $385 million primarily due to capital expenditures and foreign currency effects, partially offset by depreciation. Financial assets increased $116 million primarily due to an increase in long-term receivables from customers as well as additions to and fair value adjustments of long-term financial investments measured at FVOCI. Other non-current assets decreased $197 million, primarily due to a decrease in investments in associated companies as a result of the Aurion and Cylite transactions.

Total current assets were $6.4 billion as of December 31, 2025, an increase of $140 million when compared to $6.3 billion as of December 31, 2024. Trade receivables increased $206 million due to higher sales outpacing collections and foreign currency translation effects. Inventories increased $123 million primarily due to increases to meet expected upcoming demand and foreign currency translation effects. Cash and cash equivalents decreased $149 million due to the net impact of operating, investing and financing activities as described in the preceding section. Our cash and cash equivalents are maintained at a number of financial institutions. To mitigate the risk of uninsured balances, we select financial institutions based on their credit ratings and financial strength, and we perform ongoing evaluations of these institutions to limit our concentration risk exposure. Time deposits decreased $73 million due to the maturity of a time deposit in February 2025 offset by a time deposit purchased during the fourth quarter of 2025 with a six-month term, maturing on April 29, 2026. The time deposit is measured at amortized cost and had a carrying value of $80 million as of December 31, 2025.

Liabilities

Total non-current liabilities were $6.5 billion as of December 31, 2025, in line with December 31, 2024. Deferred tax liabilities increased $217 million primarily related to Aurion and LumiThera, partially offset by deferred tax liabilities related to intangible assets due to recurring amortization. Provisions and other non-current liabilities increased $114 million primarily due to an increase in contingent consideration liabilities primarily related to the acquisition of LumiThera and an increase in long term employee benefits and deferred compensation. Financial debts decreased $376 million primarily due to the reclassification of the Series 2026 Notes from non-current to current.

Total current liabilities were $3.0 billion as of December 31, 2025, an increase of $771 million when compared to $2.3 billion as of December 31, 2024. Financial debts increased $470 million primarily due to the reclassification of the Series 2026 Notes from non-current to current. Trade payables increased $153 million primarily due to timing of payments, raw materials purchases and foreign exchange effects. Current income tax liabilities increased $78 million primarily due to timing of payments, partially offset by tax refunds received.

The average maturity of financial debts outstanding as of December 31, 2025 is 8.8 years, and 97% of Alcon's financial debt is at fixed interest rates. We believe that we have adequate liquidity to meet our needs.

The $1.32 billion revolving credit facility remained undrawn as of December 31, 2025 and February 24, 2026. A $1.9 billion bridge loan facility was executed in August 2025 and also remained undrawn as of December 31, 2025 and was cancelled in January 2026. Refer to Note 14 to the Condensed Consolidated Interim Financial Statements for additional information.

Equity

Equity was $22.0 billion as of December 31, 2025, an increase of $482 million when compared to $21.6 billion as of December 31, 2024. Equity attributable to non-controlling interests amounted to $1 million as of December 31, 2025 related to Aurion.

------

Additional Considerations

Terminated Acquisition of STAAR Surgical Company

On August 4, 2025, Alcon entered into a definitive agreement to acquire STAAR Surgical Company ("STAAR"), a global medical technology company focused on the research, development, manufacturing, distribution and sale of phakic intraocular lenses. On August 20, 2025, Alcon executed a $1.9 billion bridge loan agreement (the "2025 Bridge Loan Facilities") with Morgan Stanley Bank International Limited and Morgan Stanley Bank, N.A., split in two tranches of $1.4 billion ("Facility A") and $0.5 billion ("Facility B"), respectively, with Alcon Finance Corporation being an additional possible borrower. Facility A was restricted for use in funding the acquisition of STAAR, whereas Facility B was to be used for financing or refinancing of any other acquisitions. The 2025 Bridge Loan Facilities remained fully undrawn as of December 31, 2025. In January 2026, Alcon terminated its definitive merger agreement with STAAR and cancelled the 2025 Bridge Loan Facilities. There were no termination fees for either company. Refer to Note 14 to the Condensed Consolidated Interim Financial Statements for additional information.

Tariffs

Beginning April 2025, the United States government announced additional tariffs on goods imported into the United States, and some nations have responded with reciprocal tariffs and other actions. Since then, there have been temporary reductions or pauses of certain tariffs to allow for trade negotiations, as well as new tariff announcements. Additional tariffs incurred in the United States and China during the three and twelve months ended December 31, 2025 amounted to $34 million and $91 million, respectively, of which $29 million and $67 million, respectively, was recognized in Cost of net sales in the Condensed Consolidated Income Statement and $24 million was recognized in Inventories in the Condensed Consolidated Balance Sheet as of December 31, 2025. Tariffs incurred for the year were lower than originally forecasted, reflecting operational and supply-chain efficiencies realized during the year. The future effects of these tariffs, along with any additional further changes in trade policies, are uncertain and could have an adverse effect on our business, financial condition, cash flows and results of operations. Further, adverse economic conditions impacting our customers or uncertainty about global economic conditions could cause purchases of our products to decline, which would adversely affect our net sales and operating results.

Refer to "Item 3. Key Information—3.D. Risk Factors—*Changing economic and financial environments in many countries and increasing global political and social instability may adversely impact our business*" in the 2025 form 20-F.

Share repurchase program

On February 25, 2025, the Company's Board of Directors authorized the repurchase of up to $750 million of the Company's common shares. The shares acquired are held in treasury and are intended to offset the dilutive effect of shares vesting under Alcon's equity-based incentive plans. Alcon funded the repurchases through cash generated from operations. The program was authorized by the Swiss Takeover Board and subject to customary safe harbor conditions. The share repurchase program was completed on January 20, 2026 with 9.3 million shares repurchased for a total of $750 million. Refer to Note 5 to the Condensed Consolidated Interim Financial Statements for details on share repurchase activity.

Federal legislation

On July 4, 2025, the United States Congress enacted budget reconciliation bill H.R. 1, which includes significant provisions such as the permanent extension of certain provisions of the Tax Cuts and Jobs Act that were set to expire. The legislation has multiple effective dates, with certain provisions effective in 2025 and others to be implemented through 2027. The enactment of H.R. 1 did not materially impact Alcon's Condensed Consolidated Financial Statements for the period ended December 31, 2025.

Alcon continues to evaluate the potential future impact of the tax law changes on our Consolidated Financial Statements, but does not expect H.R. 1 to have a material impact to the effective tax rate. The enactment of H.R. 1 resulted in a reduction in cash tax payment obligations in 2025 driven by timing of deductions.

------

Foreign currencies

We use the US Dollar as our reporting currency and are therefore also exposed to foreign currency exchange movements and costs to enter hedging agreements, primarily in Euros, Japanese Yen, Chinese Renminbi, Canadian Dollars, Singaporean Dollars, Swiss Francs, Russian Rubles and emerging market currencies. The foreign currency exposure on the balance sheet is hedged with limited exception, but the impact of ongoing macroeconomic conditions is currently unknown and could have a material adverse effect on our results of operations, cash flows or financial condition.

------

**CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS OF ALCON INC.**

Consolidated Income Statement (unaudited)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Three months ended December 31** | **Three months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** |
| ($ millions except earnings per share) | Note | **2025** | **2024** | **2025** | **2024** |
| **Net sales** | 3 | **2702** | **2477** | **10319** | **9836** |
| Other revenues | 3 | 16 | 25 | 82 | 75 |
| **Net sales and other revenues** |  | **2718** | **2502** | **10401** | **9911** |
| Cost of net sales |  | (1189) | (1093) | (4592) | (4328) |
| Cost of other revenues |  | (13) | (24) | (64) | (71) |
| **Gross profit** |  | **1516** | **1385** | **5745** | **5512** |
| Selling, general & administration |  | (901) | (802) | (3449) | (3250) |
| Research & development |  | (273) | (232) | (990) | (876) |
| Other income |  | 5 | 61 | 169 | 77 |
| Other expense |  | (34) | (17) | (115) | (50) |
| **Operating income** |  | **313** | **395** | **1360** | **1413** |
| Interest expense |  | (53) | (48) | (204) | (192) |
| Other financial income & expense |  | 6 | 9 | 22 | 43 |
| Share of (loss) from associated companies | 13 | (2) | (7) | (18) | (8) |
| **Income before taxes** |  | **264** | **349** | **1160** | **1256** |
| Taxes |  | (47) | (65) | (180) | (238) |
| **Net income** |  | **217** | **284** | **980** | **1018** |
| *Net income attributable to:* |  |  |  |  |  |
| &nbsp;&nbsp;*Shareholders of Alcon Inc.* |  | 217 | 284 | 980 | 1018 |
| &nbsp;&nbsp;*Non-controlling interests* |  |  |  |  |  |
| Earnings per share ($)<sup>(1)</sup> |  |  |  |  |  |
| Basic |  | 0.44 | 0.57 | 1.99 | 2.06 |
| Diluted |  | 0.44 | 0.57 | 1.98 | 2.05 |
| Weighted average number of shares outstanding (millions) |  |  |  |  |  |
| Basic | 5 | 489.3 | 494.7 | 493.2 | 494.4 |
| Diluted | 5 | 492.3 | 498.1 | 496.2 | 497.5 |

---

(1) Earnings per share is calculated on the amount of net income attributable to shareholders of Alcon Inc.

The accompanying Notes form an integral part of the Condensed Consolidated Interim Financial Statements.

------

Consolidated Statement of Comprehensive Income (unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** |
|<br>($ millions) | **2025** | **2024** | **2025** | **2024** |
| **Net income** | **217** | **284** | **980** | **1018** |
| *Other comprehensive income to be eventually recycled into the Consolidated Income Statement:* |  |  |  |  |
| Currency translation effects, net of taxes<sup>(1)</sup> | 1 | (141) | 176 | (116) |
| **Total of items to eventually recycle** | **1** | **(141)** | **176** | **(116)** |
| *Other comprehensive income never to be recycled into the Consolidated Income Statement:* |  |  |  |  |
| Actuarial gains from defined benefit plans, net of taxes<sup>(2)</sup> | 2 | 13 | 6 | 14 |
| Fair value adjustments on equity investments, net of taxes<sup>(3)</sup> | (17) | (34) | 27 | 36 |
| **Total of items never to be recycled** | **(15)** | **(21)** | **33** | **50** |
| **Total comprehensive income** | **203** | **122** | **1189** | **952** |
| *Total comprehensive income for the period attributable to:* |  |  |  |  |
| &nbsp;&nbsp;*Shareholders of Alcon Inc.* | 203 | 122 | 1189 | 952 |
| &nbsp;&nbsp;*Non-controlling interests* |  |  |  |  |

---

(1)Amounts are net of tax benefit of $0.1 million and $2 million for the three months ended December 31, 2025 and 2024, respectively. Amount is net of tax expense of $2 million for the twelve months ended December 31, 2025. Amount is net of tax benefit of $1 million twelve months ended December 31 2024.

(2)Amounts are net of tax expense of $2 million and $3 million for the three months ended December 31, 2025 and 2024, respectively. Amounts are net of tax expense of $3 million and $5 million for the twelve months ended December 31, 2025 and 2024, respectively.

(3)Amount is net of tax expense of $0.4 million for the three months ended December 31, 2025. Amount is net of tax benefit of $7 million for the three months ended December 31, 2024. Amounts are net of tax expense of $4 million and $16 million for the twelve months ended December 31, 2025 and 2024, respectively.

The accompanying Notes form an integral part of the Condensed Consolidated Interim Financial Statements.

------

Consolidated Balance Sheet (unaudited)

---

| | | | |
|:---|:---|:---|:---|
| ($ millions) | Note | **December 31, 2025** | **December 31, 2024** |
| **Assets** |  |  |  |
| **Non-current assets** |  |  |  |
| Property, plant & equipment |  | 4774 | 4389 |
| Right-of-use assets |  | 447 | 449 |
| Goodwill |  | 9256 | 8946 |
| Intangible assets other than goodwill | 6 | 9006 | 8587 |
| Deferred tax assets |  | 458 | 421 |
| Financial assets | 8 | 768 | 652 |
| Other non-current assets |  | 397 | 594 |
| **Total non-current assets** |  | **25106** | **24038** |
| **Current assets** |  |  |  |
| Inventories |  | 2391 | 2268 |
| Trade receivables |  | 1942 | 1736 |
| Income tax receivables |  | 20 | 23 |
| Cash and cash equivalents |  | 1527 | 1676 |
| Time deposits | 8 | 80 | 153 |
| Other current assets |  | 489 | 453 |
| **Total current assets** |  | **6449** | **6309** |
| **Total assets** |  | **31555** | **30347** |
| **Equity and liabilities** |  |  |  |
| **Equity** |  |  |  |
| Share capital |  | 20 | 20 |
| Reserves |  | 22014 | 21533 |
| **Equity attributable to shareholders of Alcon Inc.** |  | 22034 | 21553 |
| Non-controlling interests | 12 | 1 |  |
| **Total equity** |  | **22035** | **21553** |
| **Liabilities** |  |  |  |
| **Non-current liabilities** |  |  |  |
| Financial debts | 7 | 4162 | 4538 |
| Lease liabilities |  | 429 | 429 |
| Deferred tax liabilities |  | 941 | 724 |
| Provisions & other non-current liabilities |  | 939 | 825 |
| **Total non-current liabilities** |  | **6471** | **6516** |
| **Current liabilities** |  |  |  |
| Trade payables |  | 926 | 773 |
| Financial debts | 7 | 575 | 105 |
| Lease liabilities |  | 80 | 68 |
| Current income tax liabilities |  | 182 | 104 |
| Provisions & other current liabilities |  | 1286 | 1228 |
| **Total current liabilities** |  | **3049** | **2278** |
| **Total liabilities** |  | **9520** | **8794** |
| **Total equity and liabilities** |  | **31555** | **30347** |

---

The accompanying Notes form an integral part of the Condensed Consolidated Interim Financial Statements.

------

Consolidated Statement of Changes in Equity (unaudited)

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Attributable to shareholders of Alcon Inc.** | **Attributable to shareholders of Alcon Inc.** | **Attributable to shareholders of Alcon Inc.** | **Attributable to shareholders of Alcon Inc.** | **Attributable to shareholders of Alcon Inc.** | **Attributable to shareholders of Alcon Inc.** | **Attributable to shareholders of Alcon Inc.** | | |
| ($ millions) | **Share capital** | **Other reserves** | Fair value adjustments on equity investments | Actuarial gains from defined benefit plans | Cumulative currency translation effects | **Total value adjustments**<sup>(1)</sup> | **Total** | **Non-controlling interests** | **Total equity** |
| **Balance as of January 1, 2024** | **20** | **20624** | **(32)** | **37** | **(25)** | **(20)** | **20624** | **—** | **20624** |
| Net income |  | 1018 |  |  |  |  | 1018 |  | 1018 |
| Other comprehensive income/(loss) |  |  | 36 | 14 | (116) | (66) | (66) |  | (66) |
| **Total comprehensive income** | **—** | **1018** | **36** | **14** | **(116)** | **(66)** | **952** | **—** | **952** |
| Dividends |  | (131) |  |  |  |  | (131) |  | (131) |
| Equity-based compensation |  | 110 |  |  |  |  | 110 |  | 110 |
| Other movements<sup>(2)</sup> |  | 67 | (69) |  |  | (69) | (2) |  | (2) |
| **Total other movements** | **—** | **46** | **(69)** | **—** | **—** | **(69)** | **(23)** | **—** | **(23)** |
| **Balance as of December 31, 2024** | **20** | **21688** | **(65)** | **51** | **(141)** | **(155)** | **21553** | **—** | **21553** |
| Net income |  | 980 |  |  |  |  | 980 |  | 980 |
| Other comprehensive income |  |  | 27 | 6 | 176 | 209 | 209 |  | 209 |
| **Total comprehensive income** | **—** | **980** | **27** | **6** | **176** | **209** | **1189** | **—** | **1189** |
| Dividends |  | (168) |  |  |  |  | (168) |  | (168) |
| Acquisition of treasury shares |  | (682) |  |  |  |  | (682) |  | (682) |
| Equity-based compensation |  | 116 |  |  |  |  | 116 |  | 116 |
| Initial recognition of non-controlling interests |  |  |  |  |  |  |  | 27 | 27 |
| Changes in non-controlling interests |  |  |  |  |  |  |  | (26) | (26) |
| Other movements<sup>(2)</sup> |  | 36 | (10) |  |  | (10) | 26 |  | 26 |
| **Total other movements** | **—** | **(698)** | **(10)** | **—** | **—** | **(10)** | **(708)** | **1** | **(707)** |
| **Balance as of December 31, 2025** | **20** | **21970** | **(48)** | **57** | **35** | **44** | **22034** | **1** | **22035** |

---

(1) "Total value adjustments" are presented net of the corresponding tax effects.

(2)Activity includes hyperinflationary accounting. For the twelve months ended December 31, 2025, Other reserves also includes reversals of previously-recognized deferred taxes and reclassifications related to the settlements of equity investments. For the twelve months ended December 31, 2024, Other reserves also includes a reclassification related to the transfer of an equity investment to an investment in associated company and the settlement of an equity investment.

The accompanying Notes form an integral part of the Condensed Consolidated Interim Financial Statements.

------

Consolidated Statement of Cash Flows (unaudited)

---

| | | | |
|:---|:---|:---|:---|
| | | **Twelve months ended December 31** | **Twelve months ended December 31** |
| ($ millions) | Note | **2025** | **2024** |
| **Net income** |  | **980** | **1018** |
| *Adjustments to reconcile net income to net cash flows from operating activities* |  |  |  |
| Depreciation, amortization, impairments and fair value adjustments | 9.1 | 1191 | 1226 |
| Equity-based compensation expense |  | 162 | 150 |
| Non-cash change in current and non-current provisions and other non-current liabilities |  | 84 | 52 |
| Losses on disposal and other adjustments on property, plant & equipment and other non-current assets, net |  | 16 | 16 |
| Net gain on divestment of product rights | 12 |  | (57) |
| Interest expense |  | 204 | 192 |
| Other financial income & expense |  | (22) | (43) |
| Share of loss from associated companies | 13 | 18 | 8 |
| Taxes |  | 180 | 238 |
| Interest received |  | 63 | 69 |
| Interest paid |  | (190) | (182) |
| Other financial payments |  | (8) | (8) |
| Taxes paid |  | (107) | (326) |
| Net cash flows before working capital changes and net payments out of provisions and other non-current liabilities |  | 2571 | 2353 |
| Net payments out of provisions and other cash movements in non-current liabilities |  | (60) | (87) |
| Change in net current assets and other operating cash flow items | 9.2 | (240) | (189) |
| **Net cash flows from operating activities** |  | **2271** | **2077** |
| Purchase of property, plant & equipment |  | (543) | (473) |
| Proceeds from sale of property, plant & equipment |  | 5 |  |
| Purchase of intangible assets |  | (120) | (197) |
| Purchase of investments in associated companies | 13 | (8) | (159) |
| Payments for financial assets |  | (56) | (128) |
| Purchase of time deposits | 8 | (80) | (150) |
| Proceeds from time deposits | 8 | 150 |  |
| Proceeds from financial assets |  | 8 | 9 |
| Acquisitions of businesses, net of cash acquired | 12 | (692) | (61) |
| Other investing cash flows |  | (8) | (8) |
| **Net cash flows used in investing activities** |  | **(1344)** | **(1167)** |
| Dividends paid to shareholders of Alcon Inc. | 5 | (166) | (130) |
| Repayment of financial debts |  | (112) | (47) |
| Proceeds from financial debts, net of issuance costs |  | 59 | 59 |
| Other net changes in financial debts |  | 38 | (66) |
| Payments for acquisition of treasury shares | 5 | (676) |  |
| Lease payments |  | (81) | (83) |
| Payment of withholding taxes related to equity-based compensation |  | (47) | (47) |
| Transactions with non-controlling interests | 12 | (26) |  |
| Other financing cash flows |  | (108) | (8) |
| **Net cash flows used in financing activities** |  | **(1119)** | **(322)** |
| Effect of exchange rate changes on cash and cash equivalents |  | 43 | (6) |
| **Net change in cash and cash equivalents** |  | **(149)** | **582** |
| Cash and cash equivalents at January 1 |  | 1676 | 1094 |
| **Cash and cash equivalents at December 31** |  | **1527** | **1676** |

---

The accompanying Notes form an integral part of the Condensed Consolidated Interim Financial Statements.

------

**NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS OF ALCON INC. (unaudited)**

1. Selected accounting policies

Basis of preparation

These Condensed Consolidated Interim Financial Statements for Alcon Inc. ("the Company") and the subsidiaries it controls (collectively, "Alcon") have been prepared in accordance with International Accounting Standard 34, *Interim Financial Reporting,* as issued by the International Accounting Standards Board ("IASB") and with the accounting policies as described in Note 2 to the December 31, 2025 Consolidated Financial Statements in the Company's 2025 Form 20-F ("Form 20-F").

These Condensed Consolidated Interim Financial Statements do not include all of the information required for a complete set of International Financial Reporting Standards ("IFRS") financial statements. The financial information consolidates the Company and the subsidiaries it controls, and includes selected notes to explain events and transactions that are significant to an understanding of the changes in Alcon's financial position and performance since the prior annual Consolidated Financial Statements. For non-wholly owned subsidiaries, non-controlling interests are recognized to reflect the portion of equity that is not attributable, directly or indirectly, to shareholders of the Company. The Condensed Consolidated Interim Financial Statements as of December 31, 2025 and 2024 and for the years then ended are derived from and should be read in conjunction with the annual Consolidated Financial Statements for the years ended December 31, 2025 and 2024, which have been prepared in accordance with IFRS as issued by the IASB ("IFRS Accounting Standards") and can be found in the Form 20-F.

The accompanying Condensed Consolidated Interim Financial Statements present our historical financial position, results of operations, comprehensive income and cash flows in accordance with IFRS Accounting Standards. Alcon's principal accounting policies are set out in Note 2 to the Consolidated Financial Statements in the Form 20-F.

Use of estimates and assumptions

The preparation of Condensed Consolidated Interim Financial Statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the period, that affect the reported amounts of assets and liabilities as well as revenues and expenses. Because of the inherent uncertainties, actual outcomes and results may differ from management's assumptions and estimates.

Business combinations

The business combinations accounting policy was expanded in 2025 to include business combinations achieved in stages and non-controlling interests, as follows:

As discussed in Note 2 to the Consolidated Financial Statements in the Form 20-F, if the business combination is achieved in stages, the acquisition date carrying value of Alcon's previously held equity interest in the acquiree is remeasured to fair value at the acquisition date. Any gains or losses arising from such remeasurement are recognized in Other income or Other expense, respectively, in the Consolidated Income Statement.

Alcon recognizes non-controlling interests in the acquired entity either at fair value or at the non-controlling interests' proportionate share of the acquired entity's net identifiable assets. This decision is made on an acquisition-by-acquisition basis.

------

Treasury shares

The accounting policies were expanded in 2025 to include treasury shares acquired in repurchases, as follows:

As discussed in Note 2 to the Consolidated Financial Statements in the Form 20-F, common shares repurchased are measured at fair value on their trade date and include transaction costs directly attributable to the repurchase. They are held in treasury and deducted from equity. No gains or losses are recognized in the Consolidated Income Statement on the purchase or issuance of such shares. Payments for the acquisition of treasury shares are recorded in Payments for acquisition of treasury shares in the Consolidated Statement of Cash Flows.

Treasury share repurchases denominated in a currency other than the reporting currency are valued at the trade date using the spot exchange rate for the reporting currency. Any realized foreign exchange gains or losses arising between the trade date and settlement date is recognized in Other financial income & expense in the Consolidated Income Statement. If the trade date by the broker or bank and settlement date of the repurchase by the Company fall in different reporting periods, an accrued liability is recognized at period-end for the settlement obligation in Provisions & other current liabilities on the Consolidated Balance Sheet.

Impairment of goodwill, Alcon brand name and definite lived intangible assets

As discussed in Note 2 to the Consolidated Financial Statements in the Form 20-F, Goodwill, the Alcon brand name and acquired in-process research & development ("IPR&D") projects are reviewed for impairment at least annually and these, as well as all other investments in intangible assets, are reviewed for impairment whenever events or changes in circumstance indicate that the asset's balance sheet or reportable segment carrying amount may not be recoverable. Goodwill and other intangible assets represent a significant amount of total assets on the Consolidated Balance Sheet. Impairment testing may lead to potentially significant impairment charges in the future, which could have a materially adverse impact on Alcon's results of operations and financial condition.

New standards and interpretations not yet adopted

In April 2024, the IASB issued IFRS 18, *Presentation and Disclosure in Financial Statements,* which will replace IAS 1, *Presentation of Financial Statements* and accompanies limited amendments to other standards which will be effective upon the adoption of the new standard. IFRS 18 will be retroactively effective for our annual reporting periods beginning on January 1, 2027, with early adoption permitted. The standard is expected to improve comparability and transparency of financial statements by requiring defined subtotals in the Consolidated Income Statement, requiring disclosure of management-defined performance measures and adding new principles for aggregation and disaggregation of information. IFRS 18 will not impact recognition or measurement of the financial statement items. However, it may impact operating income due to the reclassification of certain income and expense items within the income statement. Additionally, it may also change the disclosure of operating activities, investing activities and financing activities within the statement of cash flows due to the change in classification of certain cash flow items. Alcon is currently evaluating the impact of adopting this standard on its Consolidated Financial Statements.

Other than previously described, as of December 31, 2025 there are no IFRS Accounting Standards, interpretations or amendments not yet effective that would be expected to have a material impact on Alcon upon adoption.

2. Significant transactions

Significant transactions in 2025

Surgical - Acquisition of LumiThera, Inc.

On September 2, 2025, Alcon closed on a merger agreement and acquired the remaining outstanding equity of LumiThera Inc. ("LumiThera"), resulting in 100% ownership when combined with Alcon's existing investment in LumiThera. LumiThera is a privately held, US-based company that developed and commercializes the *Valeda* photobiomodulation device, a multi-wavelength treatment for dry age-related macular degeneration, which supplements Alcon's Surgical portfolio. The acquisition of the equity interest was accounted for as a business combination that resulted in goodwill of $38 million after the updated preliminary purchase price allocation ("PPA") of the consideration to the fair values of acquired assets and assumed liabilities. The fair value of the assets acquired and liabilities assumed for the acquisition were based on preliminary calculations and valuations, and are subject to change as additional information is obtained during the respective measurement period up to one year from the acquisition date. Total cash paid at closing, net of cash acquired, was $124 million. Refer to Note 12 for additional information and preliminary PPA.

------

Vision Care - Acquisition of majority interest in Aurion Biotech, Inc.

On March 24, 2025, Alcon closed on agreements with certain existing shareholders of Aurion Biotech, Inc. ("Aurion") to acquire approximately 58.7% of outstanding equity for approximately $486 million and outstanding convertible notes from the same shareholders for approximately $36 million, totaling $522 million cash paid at closing. When combined with Alcon's existing 40.3% investment in Aurion, the transaction resulted in 99% ownership of Aurion on an outstanding basis. Aurion's ownership on a fully diluted basis at closing was approximately 85.0% held by Alcon and 15.0% held by non-controlling interests. This transaction supports Alcon's ophthalmic pharmaceutical portfolio expansion, including biopharmaceutical applications, with the potential to advance the first-ever corneal cell therapy candidate. The acquisition of majority interest was accounted for as a business combination that resulted in goodwill of $175 million after the final PPA of the consideration to the fair values of acquired assets and assumed liabilities. Total cash paid at closing, net of cash acquired, was $496 million. The PPA was finalized in the fourth quarter of 2025. Refer to Note 12 for additional information, including the final PPA and details related to the associated non-controlling interests.

Surgical - Acquisition of Cylite Pty Ltd.

On January 16, 2025, Alcon executed a stock purchase agreement and acquired approximately 91.2% of outstanding equity from Cylite Pty Ltd. ("Cylite") shareholders, resulting in 100% ownership when combined with Alcon's existing 8.8% investment in Cylite. The Cylite diagnostic device complements Alcon's existing Surgical portfolio for cataracts. The acquisition of the remaining equity interest was accounted for as a business combination that resulted in goodwill of $90 million after the final PPA of the consideration to the fair values of acquired assets and assumed liabilities. Total cash paid at closing, net of cash acquired, was $72 million. The PPA was finalized in the fourth quarter of 2025. Refer to Note 12 for additional information and final PPA.

Significant transactions in 2024

Divestment of product rights and out-licensing in China

On October 17, 2024, Alcon closed on a set of definitive agreements to divest its rights in China in favor of Ocumension Therapeutics (Hong Kong) Limited ("Ocumension") to *Bion Tears* and *Tears Naturale* (reported in Vision Care segment) and procedural eye drops (reported in Surgical segment). Under the terms of the agreements, Ocumension licensed the exclusive commercialization rights to *Systane* Ultra in China and development and commercialization rights to AR-15512 in China. In exchange, Alcon received up-front consideration of $116 million in the form of approximately 16.7% of the ordinary shares of Ocumension. Alcon will also receive royalties and defined AR-15512 sales milestones. Refer to Note 12 for additional information.

Surgical - Acquisition of BELKIN Vision Ltd.

On July 1, 2024, Alcon acquired 100% of the outstanding shares and equity of BELKIN Vision Ltd. ("BELKIN") as provided under the Agreement and Plan of Merger ("BELKIN Agreement"). This transaction complements Alcon's existing Surgical portfolio in the treatment of glaucoma. The acquisition was accounted for as a business combination that resulted in goodwill of $20 million after the PPA of the consideration to the fair values of acquired assets and assumed liabilities. Total cash paid at closing for the net identifiable assets recognized, net of cash acquired, was $61 million. Refer to Note 12 for additional information and final PPA.

------

3. Segmentation of key figures

The segment information disclosed in these Condensed Consolidated Interim Financial Statements reflects historical results consistent with the identifiable reportable segments of Alcon and financial information that the Chief Operating Decision Maker ("CODM") reviews to evaluate segmental performance and allocate resources among the segments. The CODM is the Executive Committee of Alcon.

The businesses of Alcon are divided operationally on a worldwide basis into two identified reportable segments, Surgical and Vision Care. Alcon's reportable segments are the same as its operating segments as Alcon does not aggregate any operating segments in arriving at its reportable segments. As indicated below, certain income and expenses are not allocated to segments.

Reportable segments are presented in a manner consistent with the internal reporting to the CODM. The reportable segments are managed separately due to their distinct needs and activities for research, development, manufacturing, distribution and commercial execution.

The Executive Committee of Alcon is responsible for allocating resources and assessing the performance of the reportable segments.

In Surgical, Alcon researches, develops, manufactures, distributes and sells ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio also includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end procedure needs of the ophthalmic surgeon.

In Vision Care, Alcon researches, develops, manufactures, distributes and sells daily disposable, reusable, and color-enhancing contact lenses, cell therapies to treat ocular diseases and a comprehensive portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma and contact lens care, as well as ocular vitamins and redness relievers.

Alcon also provides services, training, education and technical support for both the Surgical and Vision Care businesses.

The basis of preparation and the selected accounting policies mentioned in Note 1 are used in the reporting of segment results.

The Executive Committee of Alcon evaluates segmental performance and allocates resources among the segments based on net sales and segment contribution, which is the single measure of segment profitability.

Net identifiable assets are not assigned to the segments in the internal reporting to the CODM, and are not considered in evaluating the performance of the business segments by the Executive Committee of Alcon.

Segment contribution excludes amortization and impairment charges for acquired product rights or other intangibles, general and administrative expenses for corporate activities, fair value adjustments to contingent consideration liabilities, past service costs primarily for post-employment benefit plan amendments, acquisition and integration related costs, certain acquisition and divestment related items, product discontinuation costs, fair value adjustments of financial assets in the form of options to acquire a company carried at fair value through profit and loss ("FVPL"), net gains and losses on fund investments and equity securities valued at FVPL, fair value remeasurements of investments in associated companies, restructuring costs, legal provisions and settlements and other income and expense items not attributed to a specific segment.

------

Net sales and other revenues by segment

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** |
|<br>($ millions) | **2025** | **2024** | **2025** | **2024** |
| **Surgical** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Implantables | 474 | 456 | 1782 | 1775 |
| &nbsp;&nbsp;&nbsp;Consumables | 794 | 738 | 3028 | 2861 |
| &nbsp;&nbsp;&nbsp;Equipment/other | 277 | 229 | 941 | 886 |
| **Total Surgical net sales** | **1545** | **1423** | **5751** | **5522** |
| **Vision Care** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Contact lenses | 683 | 638 | 2770 | 2609 |
| &nbsp;&nbsp;&nbsp;Ocular health | 474 | 416 | 1798 | 1705 |
| **Total Vision Care net sales** | **1157** | **1054** | **4568** | **4314** |
| **Total net sales** | **2702** | **2477** | **10319** | **9836** |
| &nbsp;&nbsp;&nbsp;Surgical other revenues |  | 4 | 3 | 4 |
| &nbsp;&nbsp;Vision Care other revenues | 16 | 21 | 79 | 71 |
| **Total other revenues** | **16** | **25** | **82** | **75** |
| **Total net sales and other revenues** | **2718** | **2502** | **10401** | **9911** |

---

Segment contribution and reconciliation to income before taxes

The below tables summarize segment contribution, including material items of income and expense as required by IFRS 8, *Operating Segments,* and the associated International Financial Reporting Interpretations Committee agenda decision published in July 2024. The below tables also include a reconciliation of segment contribution to Income before taxes.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Surgical** | **Surgical** | **Vision Care** | **Vision Care** | **Not allocated to segments** | **Not allocated to segments** | **Total** | **Total** |
| | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** |
| ($ millions) | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** |
| **Net sales** | **1545** | **1423** | **1157** | **1054** | **—** | **—** | **2702** | **2477** |
| Other revenues |  | 4 | 16 | 21 |  |  | 16 | 25 |
| Cost of net sales | (587) | (540) | (416) | (374) | (186) | (179) | (1189) | (1093) |
| Cost of other revenues | (1) | (4) | (12) | (20) |  |  | (13) | (24) |
| Selling, general & administration | (413) | (379) | (398) | (342) | (90) | (81) | (901) | (802) |
| Research & development | (155) | (157) | (112) | (79) | (6) | 4 | (273) | (232) |
| Other income |  |  |  |  | 5 | 61 | 5 | 61 |
| Other expense |  |  |  |  | (34) | (17) | (34) | (17) |
| **Segment contribution and Operating income** | **389** | **347** | **235** | **260** | **(311)** | **(212)** | **313** | **395** |
| Interest expense |  |  |  |  | (53) | (48) | (53) | (48) |
| Other financial income & expense |  |  |  |  | 6 | 9 | 6 | 9 |
| Share of (loss) from associated companies |  |  |  |  | (2) | (7) | (2) | (7) |
| **Income before taxes** |  |  |  |  |  |  | **264** | **349** |

---

------

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Surgical** | **Surgical** | **Vision Care** | **Vision Care** | **Not allocated to segments** | **Not allocated to segments** | **Total** | **Total** |
| | **Twelve months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** |
| ($ millions) | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** |
| **Net sales** | **5751** | **5522** | **4568** | **4314** | **—** | **—** | **10319** | **9836** |
| Other revenues | 3 | 4 | 79 | 71 |  |  | 82 | 75 |
| Cost of net sales | (2167) | (2014) | (1649) | (1605) | (776) | (709) | (4592) | (4328) |
| Cost of other revenues | (3) | (4) | (61) | (67) |  |  | (64) | (71) |
| Selling, general & administration | (1527) | (1461) | (1587) | (1467) | (335) | (322) | (3449) | (3250) |
| Research & development | (597) | (580) | (369) | (284) | (24) | (12) | (990) | (876) |
| Other income |  |  |  |  | 169 | 77 | 169 | 77 |
| Other expense |  |  |  |  | (115) | (50) | (115) | (50) |
| **Segment contribution and Operating income** | **1460** | **1467** | **981** | **962** | **(1081)** | **(1016)** | **1360** | **1413** |
| Interest expense |  |  |  |  | (204) | (192) | (204) | (192) |
| Other financial income & expense |  |  |  |  | 22 | 43 | 22 | 43 |
| Share of (loss) from associated companies |  |  |  |  | (18) | (8) | (18) | (8) |
| **Income before taxes** |  |  |  |  |  |  | **1160** | **1256** |

---

Net sales by region<sup>(1)</sup>

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Three months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** | **Twelve months ended December 31** |
|<br>($ millions unless indicated otherwise) | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
| United States | 1193 | 44% | 1109 | 45% | 4657 | 45% | 4511 | 46% |
| International | 1509 | 56% | 1368 | 55% | 5662 | 55% | 5325 | 54% |
| **Net sales** | **2702** | **100%** | **2477** | **100%** | **10319** | **100%** | **9836** | **100%** |

---

(1) &nbsp;&nbsp;&nbsp;&nbsp;Net sales by location of third-party customer.

4. Income taxes

Federal legislation

On July 4, 2025, the United States Congress enacted budget reconciliation bill H.R. 1, which includes significant provisions such as the permanent extension of certain provisions of the Tax Cuts and Jobs Act that were set to expire. The legislation has multiple effective dates, with certain provisions effective in 2025 and others to be implemented through 2027. The enactment of H.R. 1 did not materially impact Alcon's Condensed Consolidated Financial Statements for the year ended December 31, 2025.

Alcon continues to evaluate the potential future impact of the tax law changes on our Consolidated Financial Statements, but does not expect H.R. 1 to have a material impact to the effective tax rate. The enactment of H.R. 1 resulted in a reduction in cash tax payment obligations in 2025 driven by timing of deductions.

------

5. Dividends, earnings per share and share repurchase program

Dividends

On February 25, 2025, the Company's Board of Directors (the "Board") proposed a dividend of CHF 0.28 per share, which was subsequently approved by the shareholders at the Annual General Meeting on May 6, 2025 and paid in May 2025 for an amount of $166 million.

On February 27, 2024, the Board proposed a dividend of CHF 0.24 per share, which was subsequently approved by the shareholders at the Annual General Meeting on May 8, 2024 and paid in May 2024 for an amount of $130 million.

Earnings per share

As of December 31, 2025, there were 487.4 million outstanding common shares after repurchases of 8.4 million common shares, partially offset by the delivery of 1.2 million net shares vesting under the equity incentive programs during the twelve months ended December 31, 2025.

Basic earnings per share is computed by dividing net income attributable to shareholders of Alcon Inc. for the period by the weighted average number of common shares outstanding during the period. For the three and twelve months ended December 31, 2025, the weighted average number of shares outstanding was 489.3 million and 493.2 million, respectively. For the three and twelve months ended December 31, 2024, the weighted average number of shares outstanding was 494.7 million and 494.4 million, respectively.

The only potentially dilutive securities are the outstanding unvested equity-based awards, as described in Note 10. Except when the effect would be anti-dilutive, the calculation of diluted earnings per common share includes the weighted average net impact of unvested equity-based awards. For the three and twelve months ended December 31, 2025, the weighted average diluted number of shares outstanding was 492.3 million and 496.2 million, respectively, which includes the potential conversion of 3.0 million unvested equity-based awards. For the three and twelve months ended December 31, 2024, the weighted average diluted number of shares outstanding was 498.1 million and 497.5 million, respectively, which includes the potential conversion of 3.4 million and 3.1 million unvested equity-based awards, respectively.

Share repurchase program

On February 25, 2025, the Board authorized the repurchase of up to $750 million of the Company's common shares. The shares acquired are held in treasury and are intended to offset the dilutive effect of shares vesting under Alcon's equity-based incentive plans. Alcon funded the repurchases through cash generated from operations. The program was authorized by the Swiss Takeover Board and subject to customary safe harbor conditions.

On March 27, 2025, the Company executed an agreement with a bank to set the terms on which the bank will execute the share repurchases as the Company's agent. The agreement with the bank is cancellable at any time without continuing obligation such that no financial liability exists to the Company from execution of the agreement or the approval of the program. As of December 31, 2025, 8.4 million shares were repurchased for a total consideration of $682 million. Total cash payments for acquisition of treasury shares of $676 million were recorded to Payments for acquisition of treasury shares within the financing section of the Condensed Consolidated Statement of Cash Flows. Liabilities of $6 million were recorded to Provisions & other current liabilities on the Condensed Consolidated Balance Sheet for share repurchases which were initiated but not settled as of December 31, 2025.

The share repurchase program was completed on January 20, 2026 with 9.3 million shares repurchased for a total of $750 million.

------

6. Intangible assets other than goodwill

Intangible asset impairment charges

There were no impairment charges during the three months ended December 31, 2025. Impairment charges during the twelve months ended December 31, 2025 amounted to $45 million, including $43 million recognized in Cost of net sales in the Condensed Consolidated Income Statement in the second quarter due to the full impairment of a currently marketed product cash generating unit ("CGU") in the Vision Care reportable segment due to discontinuation of commercialization of the product; and $2 million recognized in Research and development in the Condensed Consolidated Income Statement in the third quarter due to the full impairment of an acquired IPR&D CGU in the Vision Care reportable segment due to discontinuation of the project.

There were no impairment charges during the three months ended December 31, 2024. Impairment charges during the twelve months ended December 31, 2024 amounted to $9 million recognized in Research & development in the Condensed Consolidated Income Statement during the second quarter due to the full impairment of an acquired IPR&D CGU in the Surgical reportable segment due to discontinuation of the project.

7. Non-current and current financial debts

The below table summarizes non-current and current Financial debts outstanding as of December 31, 2025 and December 31, 2024.

---

| | | |
|:---|:---|:---|
| ($ millions) | **December 31, 2025** | **December 31, 2024** |
| **Non-current financial debts** |  |  |
| &nbsp;&nbsp;Local facilities (Japan), floating rate debt due 2028 | 53 |  |
| &nbsp;&nbsp;2.750% Series 2026 Notes |  | 499 |
| &nbsp;&nbsp;2.375% Series 2028 Notes | 584 | 517 |
| &nbsp;&nbsp;3.000% Series 2029 Notes | 996 | 995 |
| &nbsp;&nbsp;2.600% Series 2030 Notes | 747 | 746 |
| &nbsp;&nbsp;5.375% Series 2032 Notes | 695 | 694 |
| &nbsp;&nbsp;3.800% Series 2049 Notes | 495 | 495 |
| &nbsp;&nbsp;5.750% Series 2052 Notes | 592 | 592 |
| &nbsp;&nbsp;Revolving facility, floating rate due 2030 |  |  |
| **Total non-current financial debts** | **4162** | **4538** |
| **Current financial debts** |  |  |
| &nbsp;&nbsp;&nbsp;Local facilities, floating rate: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Japan |  | 26 |
| &nbsp;&nbsp;&nbsp;&nbsp;All others | 65 | 67 |
| &nbsp;&nbsp;2.750% Series 2026 Notes | 499 |  |
| &nbsp;&nbsp;Other short-term financial debts, floating rate | 5 | 8 |
| &nbsp;&nbsp;Derivatives | 6 | 4 |
| **Total current financial debts** | **575** | **105** |
| **Total financial debts** | **4737** | **4643** |

---

Interest expense recognized for Financial debts was $42 million and $169 million for the three and twelve months ended December 31, 2025, respectively, and $41 million and $165 million for the three and twelve months ended December 31, 2024, respectively.

------

Revolving credit facility

In September 2025, the Revolving Credit Facility was extended for one additional year to October 2030. The $1.32 billion Revolving Credit Facility remained undrawn as of December 31, 2025.

Local bilateral facilities

On January 20, 2025, three local bilateral facilities in Japan which were set to mature in February 2025 were refinanced by two facilities with three year maturities totaling $64 million (JPY 10 billion) using the FX rate as of January 20, 2025. Of that amount, $53 million was drawn as of December 31, 2025. The two local bilateral facilities are guaranteed by the Company.

8. Financial instruments

Fair value by hierarchy

As required by IFRS, financial assets and liabilities recorded at fair value in the Condensed Consolidated Interim Financial Statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. There are three hierarchical levels, based on an increasing amount of judgment associated with the inputs to derive fair value for these financial assets and liabilities, which are as follows:

Financial assets and liabilities carried at Level 1 fair value hierarchy are listed in active markets.

Financial assets and liabilities carried at Level 2 fair value hierarchy are valued using corroborated market data.

Level 1 financial assets include money market funds, equity securities in public companies and deferred compensation assets. There were no financial liabilities carried at Level 1 fair value, and Level 2 financial assets and liabilities include derivative financial instruments.

Investments in money market funds and equity securities in public companies are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. Investments in money market funds are classified as Cash & cash equivalents within the Condensed Consolidated Balance Sheet.

Deferred compensation investments for certain employee benefit plans are held in a rabbi trust and dedicated to pay the benefits under the associated plans but are not considered plan assets as the assets remain available to creditors of Alcon in certain events, including bankruptcy. Rabbi trust assets primarily consist of investments in mutual funds. These assets are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

Level 3 inputs are unobservable for the financial asset or liability. Fair value measurements classified as Level 3 are performed primarily using the income approach or market approach. The financial assets and liabilities generally included in the Level 3 fair value hierarchy are equity securities and convertible notes receivable of private companies measured at fair value through other comprehensive income ("FVOCI"), fund investments, options to acquire private companies, and contingent consideration liabilities measured at FVPL.

------

The below table summarizes financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2025 and December 31, 2024.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
|<br>($ millions) | **Level 1** | **Level 2** | **Level 3** | **Total** | **Level 1** | **Level 2** | **Level 3** | **Total** |
| **Non-current financial assets** |  |  |  |  |  |  |  |  |
| Long-term financial investments measured at FVOCI<sup>(1)</sup> | 132 |  | 196 | **328** | 81 |  | 201 | **282** |
| Long-term financial investments measured at FVPL |  |  | 4 | **4** |  |  | 1 | **1** |
| Deferred compensation assets<sup>(2)</sup> | 202 |  |  | **202** | 180 |  |  | **180** |
| **Non-current financial assets at fair value** | **334** | **—** | **200** | **534** | **261** | **—** | **202** | **463** |
| **Current financial assets** |  |  |  |  |  |  |  |  |
| Money market funds | 562 |  |  | **562** | 432 |  |  | **432** |
| Current portion of long-term financial investments measured at FVPL<sup>(3)</sup> |  |  | 1 | **1** |  |  | 1 | **1** |
| Derivative financial instruments<sup>(3)</sup> |  | 5 |  | **5** |  | 12 |  | **12** |
| **Current financial assets at fair value** | **562** | **5** | **1** | **568** | **432** | **12** | **1** | **445** |
| **Financial assets at fair value** | **896** | **5** | **201** | **1102** | **693** | **12** | **203** | **908** |
| **Non-current financial liabilities** |  |  |  |  |  |  |  |  |
| Non-current contingent consideration liabilities |  |  | (160) | **(160)** |  |  | (96) | **(96)** |
| **Non-current financial liabilities at fair value** | **—** | **—** | **(160)** | **(160)** | **—** | **—** | **(96)** | **(96)** |
| **Current financial liabilities** |  |  |  |  |  |  |  |  |
| Current contingent consideration liabilities |  |  | (9) | **(9)** |  |  |  | **—** |
| Derivative financial instruments |  | (6) |  | **(6)** |  | (4) |  | **(4)** |
| **Current financial liabilities at fair value** | **—** | **(6)** | **(9)** | **(15)** | **—** | **(4)** | **—** | **(4)** |
| **Financial liabilities at fair value** | **—** | **(6)** | **(169)** | **(175)** | **—** | **(4)** | **(96)** | **(100)** |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;As of December 31, 2024, included $11 million of Long-term convertible notes due from associated companies.

(2)&nbsp;&nbsp;&nbsp;&nbsp;Recorded in Other non-current assets.

(3)&nbsp;&nbsp;&nbsp;&nbsp;Recorded in Other current assets.

There were no transfers of financial assets or liabilities between levels in the fair value hierarchy during the twelve months ended December 31, 2025.

The carrying amount is a reasonable approximation of fair value for all other financial instruments as of December 31, 2025 and December 31, 2024, with the exception of the Series 2026, 2028, 2029, 2030, 2032, 2049 and 2052 Notes ("Notes"). As of December 31, 2025, the Notes are recorded in Non-current financial debts, with the exception of the Series 2026 Notes, which are recorded in Current financial debts. As of December 31, 2025, the Notes had a fair value of $4,466 million and a carrying value of $4,608 million. As of December 31, 2024, the Notes are recorded in Non-current financial debts. As of December 31, 2024, the Notes had a fair value of $4,240 million and a carrying value of $4,538 million. The fair value of the Notes was determined using Level 2 inputs. The Notes were valued using the quoted market price for such Notes, which have low trading volumes.

------

Level 3 financial instruments measured at fair value on a recurring basis

Financial assets

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Long-term financial investments measured <br>at FVOCI** | **Long-term financial investments measured <br>at FVOCI** | **Financial investments <br>measured at FVPL** | **Financial investments <br>measured at FVPL** |
|<br>($ millions) | **2025** | **2024** | **2025** | **2024** |
| **Balance as of January 1** | **201** | **147** | **2** | **8** |
| Additions | 42 | 116 | 5 |  |
| Net (losses)/gains recognized in Consolidated Statement of Comprehensive Income | (20) | 90 |  |  |
| Net gains recognized in Consolidated Income Statement |  |  |  | 2 |
| Amortization |  |  | (2) | (3) |
| Transfer to Other non-current assets |  | (132) |  |  |
| Settlements | (27) | (20) |  | (5) |
| **Balance as of December 31** | **196** | **201** | **5** | **2** |

---

During the prior year, net gains recognized for Level 3 Long-term financial investments measured at FVOCI primarily relate to a fair value adjustment for an equity interest in a private company. The fair value of the equity interest was determined using the market approach with Level 3 inputs that are not readily observable, primarily prices for similar securities of the same company. During 2024, Alcon acquired additional equity interest in that company and classified the investment as an associated company, which is accounted for using the equity method as Alcon is considered to have significant influence. The investment was transferred to Investments in associated companies within Other non-current assets.

Financial liabilities

---

| | | |
|:---|:---|:---|
| | **Contingent consideration liabilities** | **Contingent consideration liabilities** |
|<br>($ millions) | **2025** | **2024** |
| **Balance as of January 1** | **(96)** | **(90)** |
| Additions | (63) | (6) |
| Accretion for passage of time | (11) | (7) |
| Adjustments for changes in assumptions |  | 7 |
| Currency translation effects | 1 |  |
| **Balance as of December 31** | **(169)** | **(96)** |

---

Additions to contingent consideration liabilities in the current year period relate to the LumiThera and Cylite acquisitions. Additions to contingent consideration liabilities in the prior year period relate to the BELKIN acquisition. Refer to Note 12 for additional information.

As of December 31, 2025, the probability of success for various development and commercial milestones ranges from 0% to 95% and the maximum remaining potential payments related to contingent consideration from business combinations is $1.4 billion, plus other amounts calculated as a percentage of commercial sales in cases where there is not a specified maximum contractual payment amount. The estimation of probability typically depends on factors such as technical milestones or market performance and is adjusted for the probability of payment. If material, probable payments are appropriately discounted to reflect the impact of time.

Changes in contingent consideration liabilities in the prior year included fair value adjustments for changes in assumptions of $7 million, primarily due to revised expectations for timing of settlement for development and commercial milestones.

Contingent consideration liabilities are reported in Provisions & other non-current liabilities and Provisions & other current liabilities based on the projected timing of settlement which is estimated to range from 2026 through 2039 for contingent consideration obligations as of December 31, 2025.

------

Time deposits

During 2025, Alcon purchased time deposits of $80 million with a six-month term maturing on April 29, 2026. During 2024, Alcon purchased time deposits of $150 million with a six-month term maturing on February 17, 2025. The time deposits are measured at amortized cost and had a carrying value of $80 million and $153 million as of December 31, 2025 and 2024, respectively.

Long-term note receivable and other financial assets measured at amortized cost

As described in Note 17 to the Consolidated Financial Statements in the Form 20-F, on May 22, 2023, Alcon entered into financing arrangements with a long-term supplier, Lifecore Biomedical, Inc. and certain of its affiliates (collectively, "Lifecore") resulting in financial assets which Alcon concluded were originated credit-impaired. The maximum exposure to credit risk is reflected in the carrying value of the assets, which amounted to $192 million as of December 31, 2025, including a non-current portion of $191 million in Financial assets and a current portion of $1 million in Other current assets. As of December 31, 2025, in accordance with the terms of the Pledge and Security agreement ("security agreement"), the credit risk exposure is fully mitigated by the collateral, with an estimated amount of approximately $420 million. The estimated amount of collateral increased approximately 30% from December 31, 2024 based on updated forecasts reflecting recent market data and discounted cash flow analysis. There have been no significant changes in the quality of the collateral, the terms of the signed security agreement or the credit monitoring procedures described in Note 17 to the Consolidated Financial Statements in the Form 20-F. In addition, as of December 31, 2025, Alcon assessed there was no lifetime expected credit loss due to the value of the collateral under the security agreement.

Derivatives

The below table summarizes the net value of unsettled positions for currency derivatives contracts including swaps, forwards and options as of December 31, 2025 and December 31, 2024.

---

| | | |
|:---|:---|:---|
| ($ millions) | **December 31, 2025** | **December 31, 2024** |
| Unrealized gains in Other current assets | 5 | 12 |
| Unrealized losses in Current financial debts | (6) | (4) |
| **Net value of unsettled positions for derivatives contracts** | **(1)** | **8** |

---

There are master agreements with several banking counterparties for derivative financial instruments; however, there were no derivative financial instruments meeting the offsetting criteria under IFRS as of December 31, 2025 or December 31, 2024.

Nature and extent of risks arising from financial instruments

Note 17 to the Consolidated Financial Statements in the Form 20-F contains a summary of the nature and extent of risks arising from financial instruments. There have been no significant updates to our assessment of the nature and extent of risks arising from financial instruments or corresponding risk management policies during the period.

------

9. Condensed Consolidated Statement of Cash Flows - additional details

The below tables provide additional detail supporting select line items in the Condensed Consolidated Statement of Cash Flows.

9.1 &nbsp;&nbsp;&nbsp;&nbsp;Depreciation, amortization, impairments and fair value adjustments

---

| | | |
|:---|:---|:---|
| | **Twelve months ended December 31** | **Twelve months ended December 31** |
|<br>($ millions) | **2025** | **2024** |
| Property, plant & equipment | 417 | 393 |
| Right-of-use assets | 89 | 83 |
| Intangible assets | 829 | 752 |
| Other non-current assets<sup>(1)</sup> | (144) | (2) |
| **Total** | **1191** | **1226** |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;For the twelve months ended December 31, 2025, Other non-current assets includes gains on fair value remeasurements of investments in associated companies. Refer to Note 12 for additional information.

9.2 &nbsp;&nbsp;&nbsp;&nbsp;Change in net current assets and other operating cash flow items

---

| | | |
|:---|:---|:---|
| | **Twelve months ended December 31** | **Twelve months ended December 31** |
|<br>($ millions) | **2025** | **2024** |
| (Increase) in inventories | (156) | (47) |
| (Increase) in trade receivables | (129) | (55) |
| Increase/(decrease) in trade payables | 116 | (15) |
| Net change in other operating assets | (47) | (28) |
| Net change in other operating liabilities | (24) | (44) |
| **Total** | **(240)** | **(189)** |

---

10. Equity-based compensation

As described in Note 23 to the Consolidated Financial Statements in the Form 20-F, Alcon has various equity incentive plans, under which Alcon may grant awards in the form of restricted stock units ("RSUs"), performance-based restricted stock units ("PSUs"), restricted stock awards ("RSAs"), or any other form of award at the discretion of the Board. Certain associates in select countries may also participate in share ownership savings plans.

The below table summarizes unvested share movements for all Alcon equity-based incentive plans for the twelve months ended December 31, 2025 and 2024.

---

| | | |
|:---|:---|:---|
| | **Twelve months ended December 31** | **Twelve months ended December 31** |
|<br>(shares in millions)<sup>(1)</sup> | **2025** | **2024** |
| **Unvested at January 1** | **5.2** | **4.9** |
| Granted | 2.6 | 2.3 |
| Vested | (1.8) | (1.9) |
| Forfeited | (0.3) | (0.2) |
| **Unvested at December 31** | **5.7** | **5.2** |

---

(1) Totals may not sum due to rounding

------

11. Legal proceedings update

A number of Alcon companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability, sales and marketing practices, commercial disputes, mergers and acquisitions, employment, wrongful discharge, antitrust, securities, health and safety, environmental, tax, international trade, privacy, intellectual property, including under the Hatch-Waxman Act, and anti-bribery matters such as those under the Foreign Corrupt Practices Act of 1977 ("FCPA"), as amended.

As a result, Alcon may become subject to substantial liabilities that may not be covered by insurance and could affect Alcon's business, financial position and reputation. While Alcon does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Alcon may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow. The following is a summary as of February 24, 2026 of significant legal proceedings to which Alcon or its subsidiaries were or are currently a party and should be read in conjunction with Note 18 to the Consolidated Financial Statements in the Form 20-F.

Hatch-Waxman patent litigation

From time to time, Alcon is a party to certain patent infringement proceedings in the US in connection with Notices of Paragraph IV Certification under the Hatch-Waxman Act received from third-party generic manufacturers respecting their applications for generic versions of certain products sold by or on behalf of Alcon, including *Simbrinza, Pataday, Rhopressa* and *Rocklatan,* or other similar suits.

During the third quarter of 2022, Alcon received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying Alcon that a generic drug company filed an application with the FDA seeking pre-patent expiry approval to sell a generic version of *Simbrinza* (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%. In October 2022, Alcon filed a patent infringement lawsuit in the US District Court for the District of Delaware against that generic drug company. The lawsuit, which asserted two patents, automatically stayed FDA approval of the generic drug application for up to 30 months from receipt of the Paragraph IV Certification Letter. In August 2024, the court granted in part the generic drug company defendants' motion for summary judgment of non-infringement of the asserted patents. A trial on the remaining patent claims was held on October 21, 2024 through October 23, 2024. On February 5, 2025, the Court issued Findings of Fact and Conclusions of Law concerning the patent claims, and the defenses to those claims, that were the subject of the trial. The Court ruled that Alcon did not prove by a preponderance of the evidence that the defendant's proposed generic version of *Simbrinza* infringed the patent claims asserted at the trial. The Court also ruled that the generic drug company defendant did not prove by clear and convincing evidence that those patent claims were invalid. In the first quarter of 2025, both Alcon and the generic drug company defendant filed notices of appeal of certain rulings made by the trial court. The parties' written briefing in the appeal concluded in January 2026.

Civil Investigative Demand

In July 2024, Alcon received a Civil Investigative Demand from the US Department of Justice ("DoJ") in connection with a civil investigation under the False Claims Act relating to discounts on surgical equipment servicing contracts. Alcon is cooperating with the DoJ.

Alcon believes that its total provisions for litigation and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, additional liabilities and costs may be incurred beyond the amounts provided.

------

12. Acquisitions, divestment of product rights and out-licensing

Acquisitions of businesses

During 2025, acquisitions of businesses included LumiThera, Inc., Aurion Biotech, Inc., and Cylite Pty Ltd. During 2024, acquisition of a business included BELKIN Vision Ltd.

Surgical - Acquisition of LumiThera, Inc.

On September 2, 2025, Alcon closed on a merger agreement and acquired the remaining outstanding equity of LumiThera, resulting in 100% ownership when combined with Alcon's existing investment in LumiThera. LumiThera is a privately held, US-based company that developed and commercializes the *Valeda* photobiomodulation device, a multi-wavelength treatment for dry age-related macular degeneration, which supplements Alcon's Surgical portfolio. The acquisition of the equity interest was accounted for as a business combination that resulted in goodwill of $38 million after the updated preliminary PPA of the consideration to the fair values of acquired assets and assumed liabilities. Total cash paid at closing, net of cash acquired, was $124 million.

The potential commercial milestones payable for specified revenue targets between 2026 and 2039 could be up to $660 million and the potential development milestones payments for regulatory approval in China or Japan could be up to $30 million. The contingent consideration recognized during the third quarter of 2025 represents its fair value (Level 3) at the acquisition date.

The acquisition date fair value of the previously held financial investment measured at FVOCI by Alcon was $16 million, resulting in a remeasurement fair value gain in Other comprehensive income of $9 million, net of taxes.

During the measurement period, Alcon updated its preliminary valuation of the fair value of acquired assets and assumed liabilities, primarily due to finalization of opening balance sheet testing procedures post-acquisition date. The below table summarizes the updated preliminary PPA for the LumiThera business combination as of December 31, 2025. The PPA remains provisional and is subject to change as additional information is obtained during the respective measurement period up to one year from the acquisition date.

---

| | | | |
|:---|:---|:---|:---|
| ($ millions) | **Preliminary PPA** | **Measurement period adjustments** | **Updated preliminary PPA** |
| Current marketed products | 185 | 5 | 190 |
| Deferred tax assets | 9 |  | 9 |
| Inventories | 5 | (2) | 3 |
| Trade receivables | 2 |  | 2 |
| Cash and cash equivalents | 1 |  | 1 |
| Other current assets | 1 |  | 1 |
| Deferred tax liabilities | (42) | (2) | (44) |
| Trade payables | (2) |  | (2) |
| Provisions and other current liabilities | (3) | 1 | (2) |
| **Net identifiable assets acquired** | **156** | **2** | **158** |
| Goodwill | 42 | (4) | 38 |
| **Net assets acquired as a result of business combination** | **198** | **(2)** | **196** |
| Cash paid at closing | 126 | (1) | 125 |
| Cash expected to be paid after closing | 2 | (1) | 1 |
| Previously-held FVOCI financial investment | 16 |  | 16 |
| Contingent consideration | 54 |  | 54 |
| **Total acquisition date fair value of consideration** | **198** | **(2)** | **196** |

---

Goodwill is attributable primarily to the accounting impact of deferred tax liabilities and assembled workforce. The goodwill is not deductible for tax purposes.

------

Direct acquisition costs of $6 million were recognized in Other expense in the 2025 Condensed Consolidated Income Statement and were reported in operating cash flows in the 2025 Condensed Consolidated Statement of Cash Flows.

Pro forma financial information is not presented for the LumiThera business acquisition as it is not material to the Condensed Consolidated Financial Statements. The results of operations since the date of acquisition were not material.

Vision Care - Acquisition of majority interest in Aurion Biotech, Inc.

On March 24, 2025, Alcon closed on agreements with certain existing shareholders of Aurion to acquire approximately 58.7% of outstanding equity for approximately $486 million and outstanding convertible notes from the same shareholders for approximately $36 million, totaling $522 million cash paid at closing. When combined with Alcon's existing 40.3% investment in Aurion, the transaction resulted in 99% ownership of Aurion on an outstanding basis. Aurion's ownership on a fully diluted basis at closing was approximately 85.0% held by Alcon and 15.0% held by non-controlling interests. This transaction supports Alcon's ophthalmic pharmaceutical portfolio expansion, including biopharmaceutical applications, with the potential to advance the first-ever corneal cell therapy candidate. The acquisition of majority interest was accounted for as a business combination that resulted in goodwill of $175 million after the final PPA of the consideration to the fair values of acquired assets and assumed liabilities. Total cash paid at closing, net of cash acquired, was $496 million. The transaction also resulted in non-controlling interests, described below.

The acquisition date fair value of the equity interest previously held by Alcon was $334 million, resulting in a remeasurement fair value gain of $136 million in the first quarter of 2025. The fair value gain has been included in Other income in the 2025 Condensed Consolidated Income Statement.

During the measurement period, Alcon updated its preliminary valuation of the fair value of acquired assets and assumed liabilities, primarily due to changes in financial projections for certain operations. The below table summarizes the PPA for the Aurion business combination which was finalized in the fourth quarter of 2025.

---

| | | | |
|:---|:---|:---|:---|
| ($ millions) | **Preliminary PPA** | **Measurement period adjustments** | **Final PPA** |
| Property, plant and equipment | 3 |  | 3 |
| Right-of-use assets | 6 |  | 6 |
| Current marketed products | 105 | (40) | 65 |
| Acquired IPR&D | 825 | (5) | 820 |
| Deferred tax assets | 43 | (3) | 40 |
| Other current assets | 6 |  | 6 |
| Cash and cash equivalents | 26 |  | 26 |
| Non-current lease liabilities | (4) |  | (4) |
| Non-current financial debts | (1) |  | (1) |
| Deferred tax liabilities | (212) | 10 | (202) |
| Current financial debts | (34) |  | (34) |
| Current lease liabilities | (2) |  | (2) |
| Current income tax liabilities | (1) |  | (1) |
| Trade payables | (3) |  | (3) |
| Provisions and other current liabilities | (14) | 3 | (11) |
| **Net identifiable assets acquired** | **743** | **(35)** | **708** |
| Goodwill | 140 | 35 | 175 |
| Non-controlling interests | (27) |  | (27) |
| **Net assets acquired as a result of business combination** | **856** | **—** | **856** |
| Cash paid at closing | 522 |  | 522 |
| Previously-held investment in associated company | 334 |  | 334 |
| **Total acquisition date fair value of consideration** | **856** | **—** | **856** |

---

Goodwill is attributable primarily to assembled workforce and biopharmaceutical research and development capabilities. The goodwill is not deductible for tax purposes.

------

Direct acquisition costs of $2 million were recognized in Other expense in the 2025 Condensed Consolidated Income Statement and were reported in operating cash flows in the 2025 Condensed Consolidated Statement of Cash Flows.

Subsequent to the acquisition, the current and non-current financial debts were repaid in the second quarter of 2025.

Pro forma financial information is not presented for the Aurion business acquisition as it is not material to the Condensed Consolidated Financial Statements.

For the period from the date of the Aurion acquisition, March 24, 2025, through December 31, 2025, the acquired business increased Alcon's Net sales by $12 million and reduced Alcon's Net income by $37 million.

*Non-controlling interests*

Alcon elected to recognize the non-controlling interests in Aurion at fair value.

Non-controlling interests with a fair value of $27 million were recognized at acquisition date, comprised of common stock and vested options. The fair value of non-controlling interests was estimated using the market and income approaches, which were equally weighted. The income approach valuation utilized net present value techniques which involve significant judgment by management and include assumptions with measurement uncertainty. The estimates include cash flow projections for a five-year period based on management forecasts, sales forecasts beyond the five-year period extrapolated using long-term expected growth rates, discount rates and future tax rates. Actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using net present value techniques. Since the cash flow projections are a significant unobservable input, the fair value of the non-controlling interests was classified as Level 3 in the fair value hierarchy.

On March 26, 2025, the Aurion Board exercised its discretion under the Aurion stock plan and approved an exchange of outstanding vested options of Aurion employees for cash as settlement of their non-controlling interests in Aurion. During the third quarter of 2025, settlement agreements were executed among certain former Aurion executives, Alcon and Aurion. As part of these agreements, certain payments were made to these former executives and, additionally, Alcon acquired additional non-controlling interests in Aurion. During the fourth quarter of 2025, Alcon entered into stock purchase agreements and purchased additional non-controlling interests in Aurion. As a result, Alcon's fully diluted interest in Aurion increased from 85% on the business combination date to 99% as of December 31, 2025.

The below table summarizes movements in the non-controlling interests on a fully diluted basis from the acquisition date to the end of the reporting period.

---

| | | |
|:---|:---|:---|
| ($ millions unless indicated otherwise) | **Non-controlling interests (%)** | **Non-controlling interests** |
| Initial recognition at acquisition date | 15% | 27 |
| Changes in non-controlling interests | (14)% | (26) |
| **Non-controlling interests as of December 31, 2025** | **1%** | **1** |

---

Profits and losses attributable to non-controlling interests are calculated on an outstanding basis.

Surgical - Acquisition of Cylite Pty Ltd.

On January 16, 2025, Alcon executed a stock purchase agreement and acquired approximately 91.2% of outstanding equity from Cylite shareholders, resulting in 100% ownership when combined with Alcon's existing 8.8% investment in Cylite. The Cylite diagnostic device complements Alcon's existing Surgical portfolio for cataracts. The acquisition of the remaining equity interest was accounted for as a business combination that resulted in goodwill of $90 million after the final PPA of the consideration to the fair values of acquired assets and assumed liabilities. Total cash paid at closing, net of cash acquired, was $72 million.

The development milestone contingent consideration is related to a potential payment of up to $10 million upon achievement of the first commercial sale of a defined product within the United States. The contingent consideration recognized during the first quarter of 2025 represents its fair value (Level 3) at the acquisition date.

The acquisition date fair value of the equity interest previously held by Alcon was $14 million, resulting in a remeasurement fair value gain of $6 million in the first quarter of 2025. The fair value gain has been included in Other income in the 2025 Condensed Consolidated Income Statement.

------

The below table summarizes the PPA for the Cylite business combination which was finalized in the fourth quarter of 2025 without identifying any measurement period adjustment.

---

| | |
|:---|:---|
| ($ millions) | **Final PPA** |
| Property, plant and equipment | 1 |
| Right-of-use assets | 1 |
| Current marketed products | 4 |
| Acquired IPR&D | 33 |
| Inventories | 1 |
| Cash and cash equivalents | 6 |
| Other assets | 1 |
| Deferred tax liabilities | (11) |
| Lease liabilities | (1) |
| Trade payables | (1) |
| Provisions and other current liabilities | (1) |
| **Net identifiable assets acquired** | **33** |
| Goodwill | 90 |
| **Net assets acquired as a result of business combination** | **123** |
| Cash paid at closing | 78 |
| Cash expected to be paid after closing | 2 |
| Previously-held FVOCI financial investment | 11 |
| Previously-held commercialization rights in intangible assets | 9 |
| Contingent consideration | 9 |
| Previously-held investment in associated company | 14 |
| **Total acquisition date fair value of consideration** | **123** |

---

Goodwill is attributable primarily to buyer-specific synergies, including benefits to intraocular lens sales, development collaboration arrangement and associated development timeline reduction and assembled workforce. The goodwill is not deductible for tax purposes.

Direct acquisition costs of $1 million were recognized in Other expense in the 2025 Condensed Consolidated Income Statement and were reported in operating cash flows in the 2025 Condensed Consolidated Statement of Cash Flows.

Pro forma financial information is not presented for the Cylite business acquisition as it is not material to the Condensed Consolidated Financial Statements.

For the period from the date of the Cylite acquisition, January 16, 2025, through December 31, 2025, the acquired business reduced Alcon's Net income by $15 million.

Surgical - Acquisition of BELKIN Vision Ltd.

On July 1, 2024, Alcon acquired 100% of the outstanding shares and equity of BELKIN as provided under the BELKIN Agreement. This transaction complements Alcon's existing Surgical portfolio in the treatment of glaucoma. The acquisition was accounted for as a business combination that resulted in goodwill of $20 million after the PPA of the consideration to the fair values of acquired assets and assumed liabilities. The acquisition date fair value of the previously-held financial investments measured at FVOCI by Alcon was $20 million. Total cash paid at closing for the net identifiable assets recognized,net of cash acquired, was $61 million.

Under the BELKIN Agreement, there were additional amounts, up to $385 million, to be potentially paid upon achievement of certain commercial milestones if annual sales exceed defined targets within defined periods after closing. The contingent consideration recognized during the third quarter of 2024 totaled $6 million, which represents its fair value (Level 3) at the acquisition date.

------

The below table summarizes the PPA for the BELKIN business combination which was finalized in the third quarter of 2024.

---

| | |
|:---|:---|
| ($ millions) | **Final PPA** |
| Property, plant and equipment | 1 |
| Currently marketed products | 75 |
| Deferred tax assets | 6 |
| Inventories | 3 |
| Cash and cash equivalents | 3 |
| Other current assets | 2 |
| Deferred tax liabilities | (17) |
| Provisions and other current liabilities | (1) |
| **Net identifiable assets acquired** | **72** |
| Goodwill | 20 |
| **Net assets acquired as a result of business combination** | **92** |
| Cash paid at closing | 64 |
| Cash expected to be paid after closing | 2 |
| Previously-held FVOCI financial investments | 20 |
| Contingent consideration | 6 |
| **Total acquisition date fair value of consideration** | **92** |

---

The goodwill is primarily attributable to buyer-specific synergies and assembled workforce. The goodwill is not deductible for tax purposes.

Direct acquisition costs of $1 million were recognized in Other expense in the 2024 Condensed Consolidated Income Statement and were reported in operating cash flows in the 2024 Condensed Consolidated Statement of Cash Flows.

Pro forma financial information is not presented for the BELKIN business acquisition as it is not material to the Condensed Consolidated Financial Statements.

For the period from the date of the BELKIN acquisition, July 1, 2024, through December 31, 2024, the acquired business increased Alcon's 2024 Net sales by $1 million and reduced Alcon's 2024 Net income by $4 million.

Proposed acquisition of LENSAR, Inc.

On March 23, 2025, Alcon entered into a definitive agreement to acquire all outstanding shares of LENSAR, Inc. ("LENSAR"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, with a total consideration of up to approximately $430 million. The planned acquisition will complement Alcon's existing Surgical portfolio in the treatment of cataracts. The transaction is subject to customary closing conditions, including regulatory approval and is expected to close in the first half of 2026.

Divestment of product rights and out-licensing in China

On October 17, 2024, Alcon closed on a set of definitive agreements to divest its rights in China in favor of Ocumension to *Bion Tears* and *Tears Naturale* (reported in Vision Care segment) and procedural eye drops (reported in Surgical segment). Under the terms of the agreements, Ocumension licensed the exclusive commercialization rights to *Systane* Ultra in China and development and commercialization rights to AR-15512 in China. In exchange, Alcon received up-front consideration of $116 million in the form of approximately 16.7% of the ordinary shares of Ocumension, which Alcon is holding as a strategic investment and was designated at the closing date as Financial assets valued at FVOCI (Level 1). Related transaction costs of $2 million were also capitalized. Alcon will also receive royalties and defined AR-15512 sales milestones. There are additional amounts, up to $50 million, to be potentially received upon achievement of certain commercial milestones.

With the exception of *Systane* Ultra, the transaction was accounted for during the fourth quarter of 2024 as a divestment of product rights resulting in a net gain of approximately $57 million recognized in Other income in the 2024 Condensed Consolidated Income Statement. The net carrying value of the divested rights in China was approximately $2 million.

------

For *Systane* Ultra, the transaction will be accounted for as a supply agreement over the 15-year licensing term. The current and non-current portions of the up-front consideration allocated to the supply agreement, which amounted to $2 million and $54 million, respectively, were recorded as deferred income on the 2024 Condensed Consolidated Balance Sheet and will be recognized as Other revenues over the licensing term. Royalty revenues will be recognized in Other revenues in the Condensed Consolidated Income Statement as they are earned.

13. Related parties transactions

Investments in associated companies

As of December 31, 2025, Alcon holds voting interest of approximately 21.4% in an associated company. As of December 31, 2024, Alcon also held voting interests of approximately 40.3% in an associated company which Alcon acquired a majority interest in during 2025 and 8.8% in an associated company which was wholly acquired during 2025. Associated companies are accounted for using the equity method as Alcon is considered to have significant influence.

The below table summarizes activity related to investments in associated companies for the twelve months ended December 31, 2025 and 2024.

---

| | | |
|:---|:---|:---|
| | **Investments in associated companies** | **Investments in associated companies** |
|<br>($ millions) | **2025** | **2024** |
| **Balance as of January 1** | **293** | **10** |
| Purchases | 8 | 159 |
| Transfer from Financial assets |  | 132 |
| Share of (loss) from associated companies recognized in Consolidated Income Statement | (18) | (8) |
| Gains on fair value remeasurements recognized in Consolidated Income Statement<sup>(1)</sup> | 142 |  |
| Recognition of business combinations<sup>(1)</sup> | (348) |  |
| **Balance as of December 31** | **77** | **293** |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Refer to Note 12 for additional information.

There were no amounts due from associated companies as of December 31, 2025. As of December 31, 2024, long-term convertible notes due from associated companies included in Financial assets on the Condensed Consolidated Balance Sheet amounted to $11 million.

There were no other payments or payables to associated companies in 2025. Other payments and payables to associated companies in 2024 amounted to $2 million primarily for research and development costs.

------

14. Subsequent events

On August 4, 2025, Alcon entered into a definitive agreement to acquire STAAR Surgical Company ("STAAR"), a global medical technology company focused on the research, development, manufacturing, distribution and sale of phakic intraocular lenses. Pursuant to the terms of the agreement as amended, Alcon agreed to acquire all outstanding shares of STAAR's common stock for total consideration of approximately $1.8 billion. On January 6, 2026, Alcon terminated its definitive merger agreement with STAAR. There were no termination fees for either company.

On August 20, 2025, Alcon executed a $1.9 billion bridge loan agreement (the "2025 Bridge Loan Facilities") with Morgan Stanley Bank International Limited and Morgan Stanley Bank, N.A., split in two tranches of $1.4 billion ("Facility A") and $0.5 billion ("Facility B"), respectively. Facility A was restricted for use in funding the acquisition of STAAR, whereas Facility B was to be used for financing or refinancing of any other acquisitions. The 2025 Bridge Loan Facilities remained fully undrawn as of December 31, 2025. The maturity of the 2025 Bridge Loan Facilities was to be determined upon the completion of the related acquisitions. In January 2026, Alcon cancelled the 2025 Bridge Loan Facilities.

On February 24, 2026, Alcon announced certain efficiency measures supported by operational improvements and infrastructure investments. Alcon estimates the total cost to implement these efficiency measures to be approximately $150 million and expects the implementation to be completed in 2026.

On February 24, 2026, the Board approved the proposal to submit the 2025 financial statements of Alcon Inc. and Alcon's Consolidated Financial Statements for approval at the Annual General Meeting on April 30, 2026 and authorized these unaudited Condensed Consolidated Interim Financial Statements for release. Additionally on February 24, 2026, the Board proposed a dividend of CHF 0.28 per share to be approved at the same Annual General Meeting. If approved by the shareholders, the total dividend payments would amount to a maximum of approximately $182 million using the CHF/USD exchange rate as of February 16, 2026.

------

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This document contains, and our officers and representatives may from time to time make, certain "forward-looking statements" within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "intend," "commitment," "look forward," "maintain," "plan," "goal," "seek," "target," "assume," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our 2026 outlook, liquidity, revenue, revenue growth, gross margin, operating margin, core operating margin, core operating margin growth, effective tax rate, foreign currency exchange movements, tariff impact, non-operating expenses, earnings per share, earnings per share growth, operating cash flow, free cash flow, our plans and decisions relating to various capital expenditures, capital allocation priorities and other discretionary items such as our market growth assumptions, our social impact and sustainability plans, targets, goals and expectations, and generally, our expectations concerning our future performance.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict such as: cybersecurity breaches and technology failures that could disrupt operations; our ability to effectively manage the risks associated with transformational information technology changes such as the ethical use of artificial intelligence and disruptive technologies and the migration to cloud-based platforms; compliance with data privacy, identity protection and information security laws, particularly with the increased use of artificial intelligence; the impact of a disruption in our global supply chain, including the effect of tariffs, or important facilities, particularly when we single-source or rely on limited sources of supply; our reliance on outsourcing key business functions; the increasingly challenging economic, political and legal environment in China; global and regional economic, financial, monetary, legal, tax, political and social change; our ability to comply with anti-corruption, anti-bribery, export control, trade sanction, or similar laws; our ability to attract and retain qualified personnel; our ability to manage the risks associated with operating as a third party contract manufacturer; our success in completing strategic acquisitions, including equity investments in early-stage companies, on favorable terms or at all, and in integrating acquired businesses; the success of our research and development efforts, including our ability to innovate to compete effectively; our ability to manage the rapid evolution and adoption of artificial intelligence; terrorism, war and similar events; our ability to forecast sales demand and manage our inventory levels and the changing buying patterns of our customers; pricing pressure from changes in third party payor coverage and reimbursement methodologies; our ability to comply with all laws to which we may be subject; the ability to obtain regulatory clearance and approval of our products as well as compliance with any post-approval obligations, including quality control of our manufacturing; the effect of product recalls or voluntary market withdrawals; our ability to manage social impact and sustainability matters; our ability to properly educate and train healthcare providers on our products; our ability to protect our intellectual property; the accuracy of our accounting estimates and assumptions, including pension and other post-employment benefit plan obligations and the carrying value of intangible assets, and the adequacy of our financial reporting, accounting practices and internal controls; our ability to service our debt obligations; the need for additional financing through the issuance of debt or equity; the effects of litigation, including product liability lawsuits and governmental investigations; legislative, tax and regulatory reform; the impact of being listed on two stock exchanges; the ability to declare and pay dividends; the different rights afforded to our shareholders as a Swiss corporation compared to a US corporation; the effect of maintaining or losing our foreign private issuer status under US securities laws; and the ability to enforce US judgments against Swiss corporations.

Additional factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this document speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise. We also undertake no obligation to update the 2026 outlook as circumstances evolve.

**INTELLECTUAL PROPERTY**

This report may contain reference to our proprietary intellectual property. All product names appearing in *italics* are trademarks owned by or licensed to Alcon Inc. Product names identified by a "®" or a "™" are trademarks that are not owned by or licensed to Alcon or its subsidiaries and are the property of their respective owners.

------

**ABOUT ALCON**

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

**Connect with us on** ![facebooklogoa.gif](facebooklogoa.gif)![linkedinlogoa.gif](linkedinlogoa.gif)

<br>